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About this series
EMCDDA Risk Assessments are publications 
examining the health and social risks of 
individual new psychoactive substances.
The Risk Assessment Report consists of an 
analysis of the scientific and law enforcement 
information available on the new psychoactive 
substance under scrutiny and the implications 
of placing it under control. It is the outcome of 
a meeting convened under the auspices of the 
EMCDDA Scientific Committee.
This process is part of a three-step procedure 
involving information exchange/early warning, 
risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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Foreword
This publication presents the data and findings of the risk assessment on furanylfentanyl 
(N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide), carried out by the 
extended Scientific Committee of the EMCDDA on 23 May 2017.
The Risk Assessment Report, which was submitted to the European Commission and the 
Council of the European Union on 23 May 2017, examines the health and social risks of the 
drug, information on international trafficking and the involvement of organised crime, as 
well as a consideration of the potential implications of subjecting the drug to control 
measures. Furanylfentanyl is the fourteenth new psychoactive substance to be risk 
assessed under the terms of Council Decision 2005/387/JHA.
On the basis of the Risk Assessment Report — and on the initiative of the European 
Commission — on 15 November 2017, the Council decided that furanylfentanyl should be 
subject to control measures across the Member States. This decision was adopted in the 
final stage of the three-step process — early warning, risk assessment and control of new 
psychoactive substances — established by the Council Decision 2005/387/JHA. This 
legal framework allows the EU institutions and Member States to act on all new and 
potentially threatening narcotic and psychotropic drugs which appear on the European 
drug scene, with the EMCDDA and Europol, in collaboration with their respective networks 
playing a central role in the early detection of such substances as well as the harms 
caused by their use — information that underpins risk assessment, and, ultimately, 
decision-making.
In this respect we would like to acknowledge the excellent work done by the networks of 
the EMCDDA and Europol, as well as those of the EMA — the Reitox national focal points, 
Europol national units and the national competent authorities responsible for medicinal 
products — who played an essential role in collecting and providing national data.
Finally, we would like to thank all the participants in the risk assessment process for the 
high quality of work carried out. The resulting report is a valuable contribution at European 
level, which gives clear support to political decision-making.
Professor Dr Gerhard Bühringer  
Chair, Scientific Committee of the EMCDDA
Alexis Goosdeel 
Director, EMCDDA
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EMCDDA actions on monitoring and responding to new drugs
The EMCDDA has been assigned a key role in the detection and assessment of new drugs 
in the European Union under the terms of a Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of new psychoactive substances.
It establishes a mechanism for the rapid exchange of information on new psychoactive 
substances and provides for an assessment of the risks associated with them in order to 
permit the measures applicable in the Member States for the control of narcotic and 
psychotropic substances to be applied also to new psychoactive substances.
The three-step process involves information exchange/early warning, risk assessment and 
decision-making (see below). More detailed information can be found in the section ‘Action on 
new drugs’ of the EMCDDA’s website: www.emcdda.europa.eu/activities/action-on-new-drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange,
risk-assessment and control of new psychoactive substances:
I. Information exchange
Early-warning system (EWS) EMCDDA–Europol Joint Reports
III. Decision-making Council Decisions on control
II. Risk assessment EMCDDA Risk Assessments
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Europol–EMCDDA Joint Report on furanylfentanyl (N-phenyl-
N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide) — 
a summary
Europol–EMCDDA Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-
phenylethyl)piperidin-4-yl]-furan-2-carboxamide — in accordance with Article 5 of 
Council Decision 2005/387/JHA on the information exchange, risk assessment and 
control of new psychoactive substances
In November 2016, the EMCDDA and Europol examined the available information on a new 
psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-
carboxamide, commonly known by the abbreviation ‘furanylfentanyl’, through a joint 
assessment based upon the following criteria: (1) the amount of the material seized; 
(2) evidence of organised crime involvement; (3) evidence of international trafficking; 
(4) analogy with better-studied compounds; (5) evidence of the potential for further (rapid) 
spread; and (6) evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information available on furanylfentanyl 
satisfied criteria 4 and 6. The two organisations therefore concluded that sufficient 
information has been accumulated to merit the production of a Joint Report on 
furanylfentanyl as stipulated by Article 5.1 of the Decision. Accordingly, the NFPs, the 
Europol national units (ENUs), the EMA and the World Health Organization (WHO) were 
formally asked to provide the relevant information within six weeks from the date of the 
request, i.e. by 28 December 2016.
The resulting Joint Report on furanylfentanyl was submitted to the Council, the 
Commission and the EMA on 23 January 2017. The report concluded that the health and 
social risks, caused by the use of, the manufacture of, and traffic in furanylfentanyl, as well 
as the involvement of organised crime and possible consequences of control measures, 
could be thoroughly assessed through a risk assessment procedure as foreseen by 
Article 6 of Council Decision 2005/387/JHA.
The full text of the Joint Report can be found at: 
www.emcdda.europa.eu/publications/joint-reports/furanylfentanyl
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Risk Assessment Report on 
a new psychoactive substance: 
N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl]furan-2-carboxamide 
(furanylfentanyl)
Introduction
This Risk Assessment Report presents the summary 
findings and the conclusion of the risk assessment 
carried out by the extended Scientific Committee of the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) on the new psychoactive 
substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
furan-2-carboxamide (commonly known as 
furanylfentanyl). The report is intended for policy makers 
and decision makers in the institutions of the European 
Union.
The report has been prepared and drafted in accordance 
with the conceptual framework and the procedure set 
out in the risk assessment operating guidelines (1). It is 
written as a stand-alone document, which presents a 
summary of the information considered during the 
detailed analysis of the scientific and law enforcement 
data available at this time. The conclusion section of the 
report summarises the main issues addressed and 
reflects the opinions held by the members of the 
Scientific Committee. A list of the information resources 
considered by the Scientific Committee, including a 
detailed technical report on furanylfentanyl, is 
provided below.
The risk assessment has been undertaken in compliance 
with Article 6 of Council Decision 2005/387/JHA of 
10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive 
substances (2) (hereafter ‘Council Decision’). The 
Council Decision establishes a mechanism for the rapid 
exchange of information on new psychoactive 
(1) EMCDDA (2010), Risk assessment of new psychoactive substances: 
Operating guidelines, Publications Office of the European Union, 
Luxembourg. Available at: http://www.emcdda.europa.eu/html.cfm/
index100978EN.html
(2) OJ L 127, 20.5.2005, p. 32.
substances (hereafter ‘EU Early Warning System’ (3)) 
that may pose public health and social threats, including 
those related to the involvement of organised crime. 
Thus, it allows the institutions of the European Union 
and the Member States to act on all new narcotic and 
psychotropic substances (4) that appear on the 
European Union drug market. The Council Decision also 
provides for an assessment of the risks associated with 
these new psychoactive substances so that, if 
necessary, control measures can be applied in the 
Member States for narcotic and psychotropic 
substances (5).
Furanylfentanyl was formally notified on 3 November 
2015 by the EMCDDA on behalf of the Finnish national 
focal point, in accordance with Article 4 of the Council 
Decision. The notification related to the seizure of 0.2 g 
of powder seized on 29 June 2015 by customs in 
incoming mail from Poland. Following an assessment of 
the available information on furanylfentanyl, and in 
accordance with Article 5 of the Council Decision, on 
23 January 2017 the EMCDDA and Europol submitted a 
(3) The information exchange mechanism laid down by the Council 
Decision is operationalized as the European Union Early Warning 
System on New Psychoactive Substances (‘EU Early Warning 
System’). It is operated by the EMCDDA and Europol in partnership 
with the Reitox national focal points and Europol national units in the 
Member States, the European Commission, and the European 
Medicines Agency.
(4) According to the definition provided by the Council Decision, a ‘new 
psychoactive substance’ means a new narcotic drug or a new 
psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ 
means a substance in pure form or in a preparation that has not been 
scheduled under the 1961 United Nations Single Convention on 
Narcotic Drugs, and that may pose a threat to public health comparable 
to the substances listed in Schedule I, II or IV; ‘new psychotropic drug’ 
means a substance in pure form or in a preparation that has not been 
scheduled under the 1971 United Nations Convention on Psychotropic 
Substances, and that may pose a threat to public health comparable to 
the substances listed in Schedule I, II, III or IV.
(5) In compliance with the provisions of the United Nations Single 
Convention on Narcotic Drugs, 1961, and the United Nations 
Convention on Psychotropic Substances, 1971.
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Joint Report on furanylfentanyl (6) to the Council of the 
European Union, the European Commission, and the 
European Medicines Agency (EMA). Taking into account 
the conclusion of the Joint Report, and in accordance 
with Article 6 of the Council Decision on 28 February 
2017, the Council formally requested that ‘the risk 
assessment should be carried out by the extended 
Scientific Committee of the EMCDDA and be submitted 
to the Commission and the Council within twelve weeks 
from the date of this notification’.
In accordance with Article 6.2, the meeting to assess the 
risks of furanylfentanyl was convened under the 
auspices of the Scientific Committee of the EMCDDA 
with the participation of two additional experts 
designated by the Director of the EMCDDA, acting on 
the advice of the Chairperson of the Scientific 
Committee, chosen from a panel proposed by Member 
States and approved by the Management Board of the 
EMCDDA. The additional experts were from scientific 
fields that were either not represented, or not sufficiently 
represented on the Scientific Committee, and whose 
contribution was necessary for a balanced and 
adequate assessment of the possible risks of 
furanylfentanyl, including health and social risks. A 
further four experts participated in the risk assessment: 
two experts from the Commission, one expert from 
Europol, and one expert from the European Medicines 
Agency (EMA). The meeting took place on 23 May 2017 
at the EMCDDA in Lisbon. The risk assessment was 
carried out on the basis of information provided to the 
Scientific Committee by the Member States, the 
EMCDDA, Europol and the EMA. A list of the extended 
Scientific Committee, as well as the list of other 
participants attending the risk assessment meeting, is 
annexed to this report (page 47).
For the risk assessment, the extended Scientific 
Committee considered the following information 
resources:
 § Technical report on N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) 
(Annex 1);
 § EMCDDA–Europol Joint Report on a new 
psychoactive substance: N-phenyl-N-[1-(2-
phenylethyl)piperidin-4-yl]furan-2-carboxamide 
(furanylfentanyl) (6);
 § Open source information including scientific articles, 
official reports, grey literature, internet drug 
discussion forums and related websites (hereafter 
‘user websites’);
(6) EMCDDA (2017), EMCDDA–Europol Joint Report on a new 
psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
furan-2-carboxamide (furanylfentanyl), EMCDDA, Lisbon. Available at: 
http://emcdda.europa.eu/publications/joint-reports/furanylfentanyl
 § An unpublished in vivo pharmacology study kindly 
provided by the United States Drug Enforcement 
Administration (7);
 § Additional information provided during the course of 
the risk assessment meeting by the participants;
 § The EMCDDA operating guidelines for the risk 
assessment of new psychoactive substances (1); and,
 § Council Decision 2005/387/JHA of 10 May 2005 on 
the information exchange, risk assessment and 
control of new psychoactive substances (2).
Finally, it is important to note that this Risk Assessment 
Report contains a discussion of the available 
information on serious adverse events such as acute 
intoxications (typically presenting to hospital 
emergency departments) and deaths associated with 
furanylfentanyl. Such information is critical to the 
identification of emerging toxicological problems 
associated with new psychoactive substances within 
the European Union. In this context, it is important to 
recognise that the capacity to detect, identify, and 
report these events differ both within and between 
Member States. In the past few years, programmes 
have been introduced in some Member States to 
strengthen these capacities. The EMCDDA’s 
toxicovigilance system, which is a central component 
of the EU Early Warning System, has also been 
strengthened resulting in more information being 
available regarding serious adverse events associated 
with new psychoactive substances. Nonetheless, it is 
likely that these events remain under-detected and 
under-reported.  
Physical, chemical and 
pharmacological description
N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-
carboxamide (furanylfentanyl) is a furan-2-carboxamide 
derivative of N-phenyl-1-(2-phenylethyl)piperidin-4-
amine and structurally related to fentanyl, which is a 
propionamide (Figure 1). Furanylfentanyl contains one 
basic nitrogen atom in the piperidine ring readily forming 
salts with organic or inorganic acids (8). Fentanyl 
analogues (fentanils), have in common an aralkyl group 
attached to a 4-N-acylanilinopiperidine.
Furanylfentanyl is known from the scientific literature. 
Fentanyl is a fast but short-acting synthetic opioid that 
has been widely used in clinical practice including as an 
(7) Contract No. 224-16-050R.
(8) Note that although ‘furanylfentanyl’ can refer to 2- and to 
3-furanylfentanyl, in this report it will reference the 2- isomer 
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adjunct to general anaesthesia during surgery and for 
postoperative pain management. Furanylfentanyl is also 
structurally related to acetylfentanyl and acryloylfentanyl 
(Figure 1), both of which were the subject of an 
EMCDDA–Europol Joint Report in December 2015 and 
December 2016 following more than 30 deaths and 
more than 40 deaths, respectively.
Pharmacologically, furanylfentanyl is an opioid receptor 
agonist.
Synthetic opioids like fentanyl and related 
4-anilinopiperidine derivatives are potent analgesics. 
Initially developed in the 1960’s as part of research 
efforts to develop safer and better opioid analgesics, a 
small number of this family of compounds — alfentanil, 
fentanyl, sufentanil and remifentanil — have become 
widely used in human medicine as adjuncts to general 
anaesthesia during surgery and for pain management. 
They are available in a wide variety of formulations, such 
as liquids for injection, tablets, transdermal patches, 
lozenges and nasal sprays. Some are also used in 
veterinary medicine as general anaesthetics, for pain 
management, and, in the case of carfentanil and 
thiafentanil, to immobilise large animals. 
Fentanyl analogues first emerged on the illicit drug 
market in the United States of America in 1979. At the 
time they were not controlled under drug legislation. 
They were manufactured in clandestine laboratories and 
sold on the heroin market as heroin or ‘synthetic heroin’. 
A total of fifteen fentanils are controlled under the 
United Nations Single Convention on Narcotic Drugs, 
1961, as amended by the 1972 Protocol.
The major pharmacological effects of the fentanils, 
including their analgesic activity, are due to their activation 
of opioid receptors, and, in particular, the µ-opioid receptor. 
Besides their analgesic properties, a notable feature 
associated with µ-opioid receptor agonists is that they 
cause dose-dependent respiratory depression, in which 
overdose can be life-threatening. Other additional 
pharmacological effects include miosis, sedation, 
bradycardia, hypothermia, constipation, physical 
dependence, and changes in mood such as euphoria.
FIGURE 1  
The molecular structure, molecular formula and molecular mass of furanylfentanyl compared to fentanyl, 
acetylfentanyl, and acryloylfentanyl.
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Furanylfentanyl as free base or as its hydrochloride salt 
may occur as solids. There is no solubility data on 
furanylfentanyl or its hydrochloride salt; however due to 
its close similarity to fentanyl, the free base is expected 
to be poorly soluble in water and highly lipophilic. 
In Europe, furanylfentanyl has been seized as powder 
and in liquid solutions. In the latter case this includes 
nasal sprays. To a lesser extent, it has also been seized 
as tablets and in green ‘herbal’ material. It has also been 
sold as e-liquids for vaping in electronic cigarettes.
The analytical identification of furanylfentanyl in physical 
and biological samples is possible using several 
analytical techniques. Analytical data have been 
described using GC-MS, FTIR-ATR, GC-sIR, HPLC-TOF-
MS, LC-QTOF-MS, LC-MS/MS, TD-DART-MS, IMS, IC, 1H 
and 13C NMR.
The availability of analytical reference material is 
important for correct identification and for facilitating 
the quantification of furanylfentanyl in physical and 
biological samples; such reference materials are now 
commercially available. It should be noted that 
concentrations in blood samples can be in the sub-
nanogram per millilitre range. 
As furanylfentanyl has only been on the drug market for 
a short period of time it may not be part of most drug 
screenings and therefore may be undetected and/or 
under-reported.
Route of administration and dosage
Furanylfentanyl can be administered orally as a powder 
(including in capsules), as tablets, or as a solution (using 
nasal sprays) or by insufflation of a powder; it can also 
be administered intranasally or sublingually via a spray; 
inhaled by smoking or vaporising; and, administered 
transdermally by injection (intravenous and 
intramuscular). Furanylfentanyl has also been offered for 
sale in the form of propylene glycol/glycerol solutions 
(e.g. 30 mg/mL), presumably intended for vaporisation 
as an e-liquid in electronic cigarettes (‘vaping’). 
Discussions on user websites include the descriptions of 
blotters.
In the acute intoxications suspected to involve 
furanylfentanyl that were reported to the EMCDDA, the 
routes of administration were: nasally (using a nasal 
spray), by intramuscular injection, snorted as a powder, 
inhaled or administered orally.
In the deaths associated with furanylfentanyl, the routes 
of administration included intravenous injection, 
snorting, and mixed routes of oral and injection.
From the limited data available it is not possible to 
discern the ‘typical’ dosages administered by users. 
While a range of doses have been reported, these 
appear to differ depending on factors such as the route 
of administration, the tolerance of the users, the use of 
other drugs, and the desired effects.
Analysis of the concentration of nasal spray solutions of 
furanylfentanyl seized in Finland found that they contain 
between 1.1 and 3.2 mg/mL of the substance.
Doses reported on user websites range from 0.3 to 
1.6 mg (oral administration) and from 0.2 to 0.8 mg and 
above (insufflation). The assessment of such reports is 
problematic not least because the purity, amount and/or 
composition of the substance ingested are typically not 
known by the user. Moreover, the actual composition of 
the substance may differ over time and different 
geographical areas.
Pharmacology
Pharmacodynamics
Currently available data on the pharmacology of 
furanylfentanyl are limited to studies investigating its 
binding and functional activity at opioid receptors in 
vitro, and its antinociceptive properties in mice. Briefly, 
these data show that furanylfentanyl is a µ-opioid 
receptor agonist with antinociceptive properties similar 
to fentanyl.
Data from in vitro binding studies suggest that 
furanylfentanyl binds to the µ-opioid receptor (MOR) 
with high selectivity over the κ- (KOR) and δ-opioid 
receptors (DOR). Furanylfentanyl shows higher binding 
affinity than morphine (at MOR and DOR) and fentanyl 
(at MOR, KOR and DOR). Data from in vitro functional 
studies suggest, however, that furanylfentanyl functions 
as an agonist with lower functional efficacy when 
compared to morphine and fentanyl. 
Data from studies in mice examining the antinociceptive 
properties of furanylfentanyl found that when 
administered intravenously, the substance reduces the 
response to pain experimentally induced by heat. This 
effect may be broadly comparable to those of fentanyl 
but more potent than for morphine. The antinociceptive 
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effects of furanylfentanyl were reversed by the opioid 
antagonist naltrexone.
Pharmacokinetics
Studies on the pharmacokinetics of furanylfentanyl are 
limited to the identification of metabolites. Due to its 
lipophilicity, furanylfentanyl, like fentanyl, is expected to 
readily cross the blood-brain barrier and also diffuse into 
fat and other tissues and is thus likely to have a large 
volume of distribution. 
The pharmacokinetics and the metabolic pathway of 
furanylfentanyl are expected to share some similarities 
with other fentanils. As such, furanylfentanyl could be 
predicted to undergo metabolism by hepatic CYP450 
isoenzymes, including CYP2C19, CYP2D6, CYP3A4, and 
CYP3A5. 
A recent study using human post-mortem urine samples 
suggested the identification of nine metabolites 
including 4-ANPP. While 4-ANPP might also be present 
as a synthesis by-product, this substance does exert 
some biological activity, although at several orders of 
magnitude lower than morphine. Further studies are 
required to assess the metabolism of furanylfentanyl 
and whether the other metabolites exert biological 
activity of pharmacological and toxicological relevance.
Inter-individual genetic variability 
in metabolising enzymes
There is no information on the inter-individual genetic 
variability in metabolising enzymes for furanylfentanyl. 
For fentanyl, oxidative dealkylation by hepatic CYP3A4 
and by CYP3A5 isoenzymes to norfentanyl has been 
demonstrated. The variation of the expression of the 
genes coding for these CYP3A isoenzymes among 
populations might be of clinical significance but further 
studies are needed to address the toxicological 
consequences of such polymorphisms. 
Interactions with other substances, medicines, 
and other forms of interactions
While specific information about furanylfentanyl could 
not be identified it is conceivable that interactions 
observed with fentanyl and other opioid narcotic 
analgesics might apply. 
For example, should furanylfentanyl be metabolised by 
CYP450 3A4 and CYP450 3A5 isoenzymes, then the use 
of this substance with strong or moderate inhibitors of 
these isoenzymes (such as clarithromycin, erythromycin, 
fluconazole, grapefruit juice, indinavir, itraconazole, 
ketoconazole, nefazodone, ritonavir, saquinavir, suboxone, 
verapamil) may result in increased plasma concentration of 
furanylfentanyl which could be toxicologically significant. 
Overall, this could increase the risk of poisoning including 
potentially fatal respiratory depression.
The concomitant use of other central nervous system 
(CNS) depressants with opioid analgesics, including 
other opioids, sedatives/hypnotics (such as the 
benzodiazepines and the z-drugs), ethanol (alcohol), 
gabapentinoids (pregabalin and gabapentin), 
tranquillisers, sedating anti-histamines, and skeletal 
muscle relaxants may produce additive depressant 
effects. Of note in this respect is that polydrug use was 
common in the deaths reported to the EMCDDA, 
including the use of other CNS depressants such as 
benzodiazepines, pregabalin, gabapentin and ethanol.
The use of fentanyl with serotoninergic agents, such as 
selective serotonin re-uptake inhibitors (SSRIs) (the most 
commonly prescribed antidepressants) or serotonin 
norepinephrine re-uptake inhibitors (SNRIs) or monoamine 
oxidase inhibitors (MAOIs) has been associated with 
serotonin syndrome, a potentially life-threatening condition. 
This association is likely to extend to illicit drugs which act 
on the serotonergic system. It is not known if this 
association is also seen with furanylfentanyl.
Similar to fentanyl, the use of partial opioid agonists/
antagonists (such as buprenorphine, nalbuphine, 
pentazocine) which have high affinity to opioid receptors 
but relatively low intrinsic activity could partially antagonise 
the effects of furanylfentanyl and may induce withdrawal 
symptoms in people who are opioid dependent. It is 
unknown if such effects are possibly protective in 
individuals poisoned with furanylfentanyl or other fentanils. 
Psychological and behavioural effects
From the available data, it appears that the psychoactivity 
of furanylfentanyl is similar to that of other opioid 
analgesics which includes relaxation and euphoria; at 
higher doses, profound intoxication can be expected.
Legitimate uses
Furanylfentanyl has no established or acknowledged 
medical value or use (human or veterinary) in the 
European Union. There is no marketing authorisation 
(existing, ongoing or suspended) for furanylfentanyl in 
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the European Union nor in the Member States that 
responded to the information request from the European 
Medicines Agency (EMA) that was launched under 
Article 5 of the Council Decision. In addition, there is no 
information to suggest furanylfentanyl is used for the 
manufacture of a medicinal product or an active 
pharmaceutical ingredient (API) of a medicinal product 
in the European Union. It should be noted that there is 
no European Union database on the synthetic routes of 
all registered medicinal products.
Furanylfentanyl is used as an analytical reference 
standard and for use in scientific research. There are no 
reported uses of furanylfentanyl as a component in 
industrial, cosmetic or agricultural products. 
Chemical precursors that are used for 
the manufacture
Information on the chemical precursors and the 
synthetic methods employed for furanylfentanyl 
detected on the drug market within the European Union 
is limited. Impurities detected in a sample collected from 
a test purchase from an Internet vendor suggest the 
presence of furan-2-carboxylic acid, which would be 
consistent with hydrolysed reagents used in the 
acylation step. In addition, two countries reported 
powdered samples containing ‘synthesis by-products’ 
although these were not specified. 
The manufacture of furanylfentanyl most likely relies on 
precursors and synthetic methods similar to those used 
for the manufacture of pharmaceutical fentanyl. 
Accordingly, methods developed for the synthesis of 
fentanyl are applicable to furanylfentanyl. Most of these 
are straightforward, make use of common laboratory 
equipment and precursors, and require only basic 
knowledge of chemistry. A one-step method uses 
4-ANPP and furanoyl chloride for the manufacture of the 
substance. Use of a different acylating agent in the final 
acylation step could provide other fentanils.
Two potential precursors of fentanyl and other fentanils, 
N-phenyl-1-(2-phenylethyl)piperidin-4-amine (4-ANPP) 
as well as N-phenethyl-4-piperidone (NPP, a pre-
precursor), have been recently scheduled (9).
Due to the high potency of furanylfentanyl there is a 
serious risk of severe poisoning following accidental 
(9) Table I of the United Nations Convention against Traffic in Narcotic 
Drugs and Psychotropic Substances, 1988 
exposure during its manufacture. Extreme care must be 
taken when carrying out the final synthetic step as well 
as when purifying and handling the substance.
Health risks
Individual health risks
The assessment of individual health risks includes 
consideration of the acute and chronic toxicity of 
furanylfentanyl, as well as its dependence potential, and 
its similarities to and differences from other chemically 
or pharmacologically related substances.
It is important to note that when interpreting the 
information from acute intoxications and deaths 
reported to the EMCDDA as well as information from 
user websites, that individuals may have used other 
substances in addition to furanylfentanyl. The presence 
of and/or interaction with other substances or pre-
existing health conditions may account for some of the 
reported effects.
Furanylfentanyl is available as ready-to-use nasal sprays 
which typically contain milligram amounts of dissolved 
substance. The preparation of solutions containing 
milligram amounts of substance is inherently prone to 
mistakes in weighing and dilution which may lead to 
solutions with higher (or lower) concentrations. This may 
constitute an increased risk of acute toxicity to the 
individuals, which are unlikely to be able to control the 
exact dose of furanylfentanyl being consumed.
While specific information for furanylfentanyl is limited, 
recent seizures in Europe of nasal sprays containing 
other fentanils revealed that these have been sold in 
some cases as unlabelled bottles. In other cases users 
have also filled nasal sprays previously containing 
medicines (such as nasal decongestants) with fentanils. 
The lack of labelling increases the potential for 
accidental use by others and therefore poses a serious 
risk of poisoning.
Furanylfentanyl may be used in combination with other 
drugs (intentionally or unintentionally).
Limited data from seizures and collected samples have 
shown that furanylfentanyl has been detected in mixtures 
containing other opioids such as heroin, U-47,700, 
fentanyl, 2-fluorofentanyl, 4-fluoroisobutyrylfentanyl and 
carfentanil; as well as cocaine, caffeine, paracetamol, and 
sugars/sugar alcohols (lactose, mannitol, inositol). The 
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overall significance of these seizures is unclear; however, 
the identification of carfentanil is of serious concern given 
its potency. In addition, the identification of heroin and 
fentanyl in the seizures suggests that furanylfentanyl is 
being supplied through the illicit heroin/opioid market.
Acute toxicity
No studies were identified that have investigated the 
acute effects of furanylfentanyl and/or its metabolites in 
animal or humans. For fentanyl the estimated lethal 
dose in humans could be as low as 2 mg by 
intravenous injection.
Although in vitro studies have established that 
furanylfentanyl is a potent agonist of the µ-opioid 
receptor, it is not known whether this effect, which is 
also responsible for respiratory depression (among other 
physiological effects), would translate to high toxicity 
in humans.
Acute intoxications
Eleven acute intoxications associated with furanylfentanyl 
were reported by three countries: Germany (4 cases), 
Sweden (5), and the United Kingdom (2). Only 1 case was 
analytically confirmed from biological samples taken from 
the patient, with the remaining cases either being 
probable (1 case) or suspected cases (9). They occurred 
between November 2015 and September 2016. The 
majority of these cases related to acute poisoning 
presentations to hospital emergency departments that 
were reported to poison centres.
Where known, furanylfentanyl was administered 
intranasally using a nasal spray or snorted as a powder 
or taken orally. In one case a nasal solution was injected 
intramuscularly.
Of the acute intoxications, 9 were male and 2 were 
female. The mean age of the male cases for which an 
age was known was 23 (median 22) and ranged from 15 
to 32 years (data available for 5 cases); the female cases 
were aged 20 and 32 years. At least 6 cases required 
treatment in hospital. Three cases were classed by the 
poison centres as life-threatening or severe and one was 
classed as not life-threatening. The information was 
either unknown or not reported in the remaining 7 cases.
Use of the antidote naloxone was reported in 4 of the 
cases, with apparent reversal of the poisoning reported 
in 3 of these cases.
In 2 cases it was reported that the patient recovered; in 
the remaining 9 cases the outcome was unknown.
Reported clinical features included: miosis, 
unconsciousness, and respiratory depression; however, 
the lack of analytically confirmed drugs in the majority of 
cases hinders the interpretation of this as other drugs 
may have caused or contributed to the features 
observed. Nevertheless, such clinical features would be 
consistent with poisoning from an opioid, including 
fentanils.
Recently, a group of cocaine users in Canada were 
treated for opioid overdose symptoms in a hospital 
emergency department after they had smoked what they 
believed to have been crack cocaine. Analysis of 
samples of the drug used by the patients identified 
furanylfentanyl and cocaine in a mixture. Of particular 
note is that community members, first responders, and 
emergency department staff reported that patients 
required high doses of naloxone, in some cases up to 
3.0 mg.
Deaths
Twenty-three deaths associated with furanylfentanyl 
were reported by six countries: Estonia (4 deaths), 
Finland (1), Germany (4), Sweden (12), United 
Kingdom (1), and Norway (1). In all cases, furanylfentanyl 
was analytically confirmed from post-mortem samples.
Where known, 17 of the cases were male and 2 cases 
were female. The mean age of the males was 32.9 years 
(median 32) and ranged between 25 and 53 years; the 
age of the females were 33 and 48 years.
All the deaths occurred between November 2015 and 
February 2017; two deaths occurred in 2015, 19 in 2016 
and 2 in 2017.
Circumstantial information, as well as analysis of hair 
samples, suggests that that some of decedents were 
high-risk drug users, including opioid users.
Cause of death and toxicological significance
In 10 of the 23 deaths, furanylfentanyl was reported to 
be the cause of death or to have contributed to death; 
in 2 of these deaths furanylfentanyl was the sole drug 
present. In 3 deaths furanylfentanyl was assumed to 
have contributed to death. In 3 cases the cause of death 
was reported as an ‘overdose with drugs or narcotics’, 
with no substances explicitly mentioned. In the 
remaining 7 cases the cause of death had not yet been 
established, was not known, or was not reported.
RISK ASSESSMENTS | Furanylfentanyl Risk Assessment Report
13/49
A range of other substances were found in the deaths, 
including: benzodiazepines, gabapentinoids (pregabalin, 
gabapentin), ethanol, THC, amphetamine, MDMA, 
cocaine, antidepressants and antipsychotics. In 
11 cases, furanylfentanyl was the sole opioid present. In 
the remaining 12 cases, other opioids detected were: 
fentanyl (6 deaths), acetylfentanyl (2), buprenorphine (2), 
tilidine (2), methadone (1), 4-chloroisobutyrylfentanyl (1), 
and tramadol (1).
No information was available regarding symptoms 
experienced by the decedents prior to death.
Sufficient data was available in 19 of the 23 deaths to 
allow an analysis to evaluate the toxicological significance 
of furanylfentanyl. Of these, furanylfentanyl was either the 
cause of death or is likely to have contributed to death 
(even in presence of other substances) in 17 cases. Whilst 
other drugs may have contributed some toxicity, a 
synergistic and/or additive effect with furanylfentanyl 
would have been likely (e.g. other central nervous system 
depressants such as ethanol, benzodiazepines, other 
opioids, etc.). Nevertheless, the pharmacological opioid 
nature of furanylfentanyl means the primary toxic 
contribution could be attributed to the drug and death 
may not have occurred if furanylfentanyl had not been 
used. In 2 cases, furanylfentanyl may have contributed to 
toxicity/death but other drugs were present that may be 
also toxicologically significant and contributed. Overall, 
there is no defined ‘fatal’ concentration that can be 
assigned to furanylfentanyl but in 17 cases where 
measured, post-mortem blood concentrations between 
0.2 to 1.54 µg/L and between 0.33 to 2.74 ng/g blood 
were recorded (the latter somewhat but not exactly 
equivalent to µg/L).
Circumstances of death
In 18 of the 23 cases, it was reported that the individuals 
were found dead. Of these, at least 12 were found in a 
home environment (their own or someone else’s). 
Consequently, it was not possible to identify or evaluate 
ante-mortem symptoms (especially in relation to acute 
intoxications). In 5 cases drug paraphernalia was found 
at the scene of death, including used injecting 
equipment. Information on the circumstances of death 
for the remaining 5 cases was not available.
Where known, the routes of administration were by 
intravenous injection, snorting, and injection/oral.
Ability to operate machinery and drive
There have been no studies of the effects of 
furanylfentanyl on the ability to drive and operate 
machines. However, it is well established that opioid 
narcotic analgesics, such as fentanyl, impair the mental 
and physical ability required to drive and operate 
machines. This effect is likely to extend to 
furanylfentanyl.
Chronic toxicity
No studies were identified that investigated the chronic 
health effects of furanylfentanyl and/or its metabolites.
Abuse liability and dependence potential
There have been no studies that have investigated the 
dependence and/or abuse potential of furanylfentanyl. 
Given what is currently known about the pharmacology 
of furanylfentanyl, including some similarities to other 
fentanils and opioid narcotic analgesics, it is reasonable 
to assume that the substance has both a potential for 
abuse and dependence. Further research will be 
required in order to determine such effects.
Public health risks
The public health risks associated with furanylfentanyl 
may be categorised in terms of patterns of use (extent, 
frequency, route of administration, etc.); availability and 
quality of the drug; information, availability and levels of 
knowledge amongst users; and, negative health 
consequences. Detailed information, including data on 
sporadic versus chronic use, that allow for a 
determination of public health risks associated with 
furanylfentanyl are not available. In addition, risk of 
accidental exposure needs to be considered.
Extent, frequency, and patterns of use
There are no prevalence data on the use of furanylfentanyl 
in the European Union or elsewhere, but the available 
information does not suggest wide use of the substance.
Based on its known pharmacology and that it is sold as a 
‘legal’ replacement to illicit opioids, it would be expected 
that furanylfentanyl may be sought by those looking for 
substitutes to opioids, such as heroin and prescription 
opioids. It also appears that there is interest in this 
substance by some psychonauts.
The available data suggests that furanylfentanyl is sold 
online in small and wholesale amounts as a ‘research 
chemical’, typically as a powder. It has also been sold as 
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ready-to-use nasal sprays. Furanylfentanyl may also be 
sold on the illicit opioid market, as suggested by seizures 
where it was found in mixtures with other opioids such 
as heroin, U-47,700, fentanyl, 2-fluorofentanyl, 
4F-isobutyrylfentanyl and carfentanil. In these cases, it 
is reasonable to assume that these individuals will not 
be aware that they are consuming furanylfentanyl.
Availability and quality on the market
A total of 143 seizures have been reported by 
13 Member States and Norway. The single largest 
seizures of powder were 101 g made by customs and 
276 g made by police; while the largest seizure in liquid 
form was 974.5 mL made by police. Many of the seizures 
appeared to be made at street-level as powders and 
liquids. There have also been a small number of tablets 
seized as well as some herbal material that appeared to 
be branded as a ‘legal-high’-type product. While these 
quantities may appear relatively small they should be 
considered in the context of the high potency of 
furanylfentanyl.
A structured search by the EMCDDA in December 2016 
of online vendors of furanylfentanyl on the surface web 
identified 46 vendors. More than half appeared to be 
based in China (including Hong Kong), with a small 
number of vendors apparently based in, among other 
countries, the United States and the United Kingdom. 
Half of the sites listed quantities and prices.
Furanylfentanyl was typically offered in powder form 
and listed as a ‘research chemical, not fit for human 
consumption’. The amounts offered ranged from 1 g 
(EUR 54) up to 5 kg (corresponding to EUR 5.9 per 1 g).
One site offered furanylfentanyl as a ready-to-use nasal 
spray and also liquid intended for vaping in electronic 
cigarettes. This site also offered furanylfentanyl in 
powder form mixed with either mannitol (ratio of 1:10) or 
caffeine (ratio of 1:25).
Furanylfentanyl has also been sold on darknet 
marketplaces.
Characteristics and behaviour of users
No studies were identified that have examined the 
characteristics and behaviours of users of 
furanylfentanyl. Nonetheless, information from police 
seizures as well as investigations into deaths indicates 
that furanylfentanyl is available to and being used by 
high-risk drug users, including opioid users. The 
available information, including from user websites, 
suggests that some may use furanylfentanyl as a 
substitute for illicit opioids and prescription opioids; this 
includes for self-medication, such as the alleviation of 
pain and/or opioid withdrawal. Finally, some users (such 
as psychonauts) may be experimenting with this opioid.
Information from user websites suggests that users are 
generally aware of the opioid-like (wanted and 
unwanted) effects of this substance. In addition, 
information from police seizures suggests that some 
users, particularly those consuming furanylfentanyl in 
mixtures with other illicit opioids such as heroin, may not 
be aware that they are consuming the substance.
In most of the acute intoxications suspected to involve 
furanylfentanyl that were reported to the EMCDDA, the 
patients were reported to have taken ‘furanylfentanyl’.
The available information, including deaths reported by 
the Member States and from user websites, suggests 
that furanylfentanyl is used in the home environment. In 
the majority of the deaths reported to the EMCDDA the 
individuals were found dead, often in a home 
environment (their own or someone else’s). It appears 
that in at least some of these cases the poisoning with 
furanylfentanyl was so severe that they were unable to 
call for help.
Information from the deaths reported to the EMCDDA 
found that in almost half of the deaths, furanylfentanyl 
was the sole opioid present, suggesting that they may 
have had no tolerance to opioids. In addition, polydrug 
use was common, including the use of other CNS 
depressants.
Nature and extent of health consequences
While information on the nature and extent of health 
consequences related to furanylfentanyl are limited, 
there are a number of general considerations related to 
fentanils as a group.
Among other adverse effects, opioid analgesics, such as 
fentanyl, produce dose-dependent respiratory 
depression. This risk is greater in persons with no 
tolerance to opioids. Similar to other fentanils in 
overdose, the most serious acute risk arising from the 
use of furanylfentanyl appears to be from profound and 
rapid respiratory depression, which can lead to apnoea, 
respiratory arrest, and death. This risk may be 
exacerbated given: the difficulty of diluting fentanils; the 
lack of experience of users with this new substance (in 
terms of a lack of familiarity with how to use it, the 
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effects and dose of the substance); the concomitant use 
of other CNS depressants (such as other opioids, 
benzodiazepines, gabapentinoids, and ethanol); in some 
cases no apparent tolerance to opioids; and, the 
environment in which the substance is used — typically 
in the home environment.
In the past few years, new dosage forms — such as 
ready-to-use nasal sprays, home-made transdermal 
patches and e-liquids for vaping — along with open 
sales on the surface web and darknet marketplaces add 
to the complexity of the problem caused by the fentanils. 
They have become easier to get hold of and easier to use. 
The Committee is concerned about whether the 
availability of ‘novel’ dosage forms has the potential to 
make the use of fentanils more socially acceptable.
An additional challenge in respect to reducing risk in 
users and potential users, is the balance between 
providing information to prevent harm and the unintended 
consequences of communicating the risks of opioids. 
There is evidence that using terms to describe them as 
‘potent’, ‘strong’, ‘deadly’, and ‘toxic’ can lead some 
individuals to specifically seek out these substances. 
Such unintended promotion of the substances may also 
extend to former users and other groups.
Clinical experience with poisonings has found that the 
antidote naloxone will reverse poisoning (overdose) 
caused by furanylfentanyl. However, repeated doses 
may be required to fully reverse poisoning. Clinical and 
community experience in treating poisonings caused by 
exposure to fentanils supports this assertion.
In the past two years a number of outbreaks of mass 
poisoning caused by fentanils have been reported 
particularly in the United States and Canada. These types 
of outbreaks have had the potential to overwhelm 
emergency departments and deplete stocks of naloxone. 
Stocks and availability of the naloxone, as well as adequacy 
of training in how to resuscitate poisoned patients both in 
clinical and community settings may need to be assessed. 
This might include a review of the availability of naloxone to 
users through take-home naloxone programmes.
Accidental exposure of furanylfentanyl and other 
fentanils — such as skin contact, inhalation, or ingestion 
— also poses a risk of poisoning to those who may come 
into contact with the substances. This includes the 
family and friends of users, law enforcement, emergency 
personnel, medical and forensic laboratory personnel as 
well as custodial settings and postal services. In 
addition to exercising extreme caution when handling 
materials suspected to contain fentanils, working 
environments and personnel should be equipped with 
appropriate protective equipment. The antidote 
naloxone should be readily available to personnel in 
sufficient quantities; training in resuscitation and 
naloxone administration should also be available.
Adding to these challenges is evidence from Europe, the 
United States, and Canada that fentanils are being sold 
to unsuspecting users in/as heroin, counterfeit 
medicines (including commonly used opioid analgesics 
and benzodiazepines), cocaine, and other illicit drugs. As 
users will be unaware of this, it increases the risk of 
severe and fatal poisoning in both opioid users and 
especially other groups who may have no existing 
tolerance to opioids. Non-opioid users are unlikely to be 
aware of these risks and are unlikely to have access to 
community opioid overdose prevention programmes, 
including take-home naloxone programmes.
Long-term consequences of use
There is no information on the long-term consequences 
of use of furanylfentanyl.
Conditions under which the substance is obtained 
and used
There is limited information on the conditions which 
furanylfentanyl is obtained and used. It appears 
furanylfentanyl has been sold on the surface web and 
darknet marketplaces, typically as powders but also as 
ready-to-use nasal sprays. A small number of e-liquids 
for use in electronic cigarettes have also been reported.
Furanylfentanyl has also been advertised on darknet 
marketplaces. In some cases the substance also 
appears to be sold by street-level drug dealers, including 
on the illicit opioid market.
A small number of cases have confirmed that 
furanylfentanyl has been advertised and sold on the 
darknet as other opioids (including methadone, 
carfentanil, fentanyl). Two samples containing 
furanylfentanyl were purchased as the synthetic opioid 
U-47,700.
Overall, furanylfentanyl may be directly sought by some 
users, whilst others, such as those that purchase it at 
street-level, may be unaware that they are using 
furanylfentanyl. This presents an inherent risk to the 
individuals.
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Social risks
While there have been no studies on the social risks of 
furanylfentanyl, it is likely that some of the risks are 
similar to those seen with illicit opioids, such as heroin 
and prescription opioids including fentanyl.
Individual social risks
There is no information on whether the use of 
furanylfentanyl causes individual social risks; however, 
they may have some similarities with those associated 
with the use of illicit opioids, including fentanyl. These 
may impact on education or career, family or other 
personal and social relationships and may result in 
marginalisation.
Possible effects on direct social environment 
(e.g. neglect of family, violence)
There is no information on the possible effects of 
furanylfentanyl on the direct social environment; 
however, they may have some similarities with those 
associated with the use of illicit opioids.
Possible effects on society as a whole (public 
order and safety, acquisitive crime)
There is no specific information on the possible effects 
of furanylfentanyl on society as a whole.
As discussed above, accidental exposure of 
furanylfentanyl and other fentanils — such as skin 
contact, inhalation, or ingestion — also poses a risk of 
poisoning to those who may come into contact with the 
substances. This includes the family and friends of 
users, law enforcement, emergency personnel, medical 
and forensic laboratory personnel as well as custodial 
settings and postal services. Where required, these risks 
should be assessed and appropriate procedures, 
training, and protective measures should be 
implemented. This may include training in resuscitation 
and adequate provision of naloxone to reverse poisoning.
Economic costs
There are no data on the effects of furanylfentanyl in 
respect to its health and social costs. However, it is likely 
that even at low prevalence this drug has the potential to 
generate relatively high costs to health services.
Possible appeal to specific population groups
Whilst no specific examples are available on the 
possible appeal of furanylfentanyl to specific user 
groups, it is reasonable to assume furanylfentanyl may 
be sought by those looking for substitutes for illicit 
opioids, such as heroin and/or prescription opioids.
In addition, concerns exist over novel dosage forms 
— such as ready-to-use and home-made nasal sprays and 
e-liquids for vaping — which have the potential to make 
the use of fentanils easier (with similar effects to 
injecting) and more socially acceptable. Further research 
is required on this topic to better understand the risks.
Information on manufacturing, 
trafficking, distribution, and the level 
of involvement of organised crime
There is no specific information to suggest the 
involvement of organised crime or established criminal 
groups in the manufacture, distribution and supply of 
furanylfentanyl.
In the cases where the origin of the seizures/collected 
samples reported to the EMCDDA was known, the 
country of origin indicated was: Poland (20 seizures); the 
United Kingdom (1) and China (1).
Information from seizures in four Member States that 
were reported to Europol shows that some 
furanylfentanyl on the market in Europe has been 
produced by chemical companies based in China.
In addition to importation, the seizure of an illicit 
laboratory in Europe in 2013 that was producing 
fentanils, that may have included furanylfentanyl, 
suggests that the production in Europe cannot be 
excluded. This recent case demonstrates the capability 
to manufacture fentanils exists within the 
European Union.
In 7 seizures made by Belgian customs the country of 
destination of the seizure was: Spain (1), Germany (3), 
France (1), the Netherlands (1) and Slovenia (1).
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Information on any assessment in 
the United Nations system
The World Health Organization (WHO) is the specialised 
United Nations agency designated for the evaluation of 
the medical, scientific and public health aspects of 
psychoactive substances under the Single Convention 
on Narcotic Drugs, 1961, and the Convention on 
Psychotropic Substances, 1971. At the time that the 
Joint Report was prepared (6), the WHO informed the 
EMCDDA that furanylfentanyl was not currently under 
assessment nor had it been under assessment by the 
United Nations system.
On 12 May 2017, WHO informed the EMCDDA that 
furanylfentanyl will be reviewed at the 39th Expert 
Committee on Drug Dependence that will take place in 
November 2017.
Description of the control measures that 
are applicable in the Member States
Ten Member States (Czech Republic, Cyprus, Denmark, 
Estonia, Finland, Latvia, Lithuania, Slovenia, Sweden and 
the United Kingdom) and Turkey reported that 
furanylfentanyl is controlled under drug control legislation.
 § In the Czech Republic, furanylfentanyl is included in the 
amendment of Government Regulation No. 463/2013 
Coll., which entered into force on 1 March 2017.
 § In Cyprus, furanylfentanyl is controlled within the 
context of a generic clause which addresses fentanyl 
chemical groups.
 § In Denmark, it is included in the amendment of the 
Executive Order on Euphoriant Substances which 
entered into force on 24 November 2016.
 § In Estonia furanylfentanyl is controlled by way of 
generic definition.
 § In Finland, the substance is controlled as a narcotic 
since 1 April 2016.
 § In Latvia, furanylfentanyl is included in the Cabinet 
Regulation N 847 ‘Regulations regarding Narcotic 
Substances, Psychotropic Substances and 
Precursors to be Controlled in Latvia’ and the law ‘On 
the Procedures for the Coming into force and 
Application of the Criminal Law’.
 § In Lithuania, furanylfentanyl is subjected to control 
measures by The Republic of Lithuania Minister of 
Health Order No V-1511 (28/12/2015) ‘On the 
amendment of the Ministry of Health of the Republic 
of Lithuania Order No. 5 of 6 January 2000’.
 § In Slovenia, furanylfentanyl was classified as a 
‘category 1 illicit drug’, which includes 'psychoactive 
substances that are extremely dangerous to health 
due to serious consequences that may result from 
abuse and that are not used for medicinal purposes'. 
The amended decree on the classification of illicit 
drugs was published in the Official Gazette of the 
Republic of Slovenia on 24 March 2017.
 § In Sweden, furanylfentanyl is regulated as a narcotic, 
as of 25 January 2017.
 § In the United Kingdom, furanylfentanyl is controlled 
under the Misuse of Drugs Act 1971 by way of a 
generic definition.
 § In Turkey, furanylfentanyl is under control of Drug Law 
on Drugs numbered 2313 (Official Gazette 29790 of 
3 August 2016).
Three Member States (Austria, Hungary and Poland) 
reported that furanylfentanyl is controlled under specific 
new psychoactive substances control legislation.
 § In Austria, furanylfentanyl is covered by the Austrian 
Act on New Psychoactive substances.
 § In Hungary, furanylfentanyl is listed in the ministerial 
decree No. 55/2014 (XII.3.) EMMI since 25 December 
2016 (10). 
 § In Poland, furanylfentanyl is controlled according to the 
general definition of the ‘substitute drug’. Pursuant to 
Article 44b of the Act on counteracting drug addiction 
and Article 27c of the Act of 14 March 1985 on State 
Sanitary Inspection (Journal of Laws ‘Dz. U.’ of 2011, 
No. 212, item 1263), it is prohibited to manufacture 
and introduce substitute drugs to trade (11).
Germany reported that it is still under consideration 
whether furanylfentanyl is controlled under specific NPS 
control legislation.
Norway reported that furanylfentanyl is controlled by the 
Medicinal Products Legislation. 
Fourteen Member States (Belgium, Bulgaria, Croatia, 
France, Greece, Ireland, Italy (12), Luxembourg, Malta, 
the Netherlands, Portugal, Romania, Slovakia, and 
Spain) reported that furanylfentanyl is not subject to 
control measures at the national level.
(10) In addition, since 5 May 2017, furanylfentanyl has been controlled 
under the newly defined generic definition for a group of fentanyl 
analogues by ministerial decree No. 6/2017. (V. 2.) that amended 
decree No. 55/2014 (XXII.3.) on New Psychoactive Substances.
(11) There is a recommendation of the Risk Assessment Team to place 
furanylfentanyl on the list of controlled substances in schedules of act 
of counteracting drug addiction. 
(12) In February 2017, the National Institute of Health, following the formal 
request of the Ministry of Health, proposed the inclusion of 
furanylfentanyl in Table I of Presidential Decree 309/90 of illicit 
psychotropic substances. 
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Options for control and the possible 
consequences of the control measures
Under Article 9.1 of the Council Decision, the option for 
control that is available at European Union level is for the 
Member States to submit the new psychoactive 
substance furanylfentanyl to control measures and 
criminal penalties, as provided for under their legislation, 
by virtue of their obligations under the Single Convention 
on Narcotic Drugs of 1961.
Furanylfentanyl was controlled in China as of the 
1 March 2017. This control measure may at least deter 
the open manufacture and sale of this substance by 
chemical companies in this country, which are linked to 
the supply of the substance in Europe.
There are no studies on the possible consequences of 
such control measures on furanylfentanyl. If this option 
of control is pursued, the Committee considers that the 
following consequences are possible. Some of these 
may apply to any new psychoactive substance.
 § This control option could be expected to limit the 
availability of furanylfentanyl and hence the further 
expansion of the current open trade in this substance.
 § A health consequence that might result from this 
control option is the benefit brought about by the 
presumed reduction in availability and use.
 § This control option could facilitate the detection, 
seizure and monitoring of furanylfentanyl related to 
its unlawful manufacture, trafficking and use. In so 
doing, it could facilitate cooperation between the 
judicial authorities and law enforcement agencies 
across the European Union.
 § This control option would imply additional costs for 
the criminal justice system, including forensic 
services, law enforcement, and the courts.
 § This control option could lead to replacement with 
other (established or new) psychoactive substances, 
which may in themselves have public health 
consequences and social risks.
 § This control option could create an illicit market in 
furanylfentanyl with the increased risk of associated 
criminal activity, including the involvement of 
organised crime.
 § This control option could impact on both the quality/
purity and price of any furanylfentanyl still available 
on the illicit market. The extent to which this will 
impact on public health, criminality, or levels of use, is 
difficult to predict.
 § It is difficult to predict the impact of this control 
option on current or future research by the 
pharmaceutical or chemical industries.
 § In order to examine the consequences of control, the 
Committee wishes to note that it will be important to 
monitor for the presence of furanylfentanyl on the 
market post-control, should this control option be 
pursued.
 § Aside from the option for control under those 
stipulated in Article 9.1 of the Council Decision, other 
options for control may be available to Member 
States. These may include restricting the importation 
and supply of the substance as some Member States 
have already done. 
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Conclusion
N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-
carboxamide (furanylfentanyl) is a synthetic opioid and 
is structurally related to fentanyl, a controlled substance 
widely used in medicine as an adjunct to general 
anaesthesia during surgery and for pain management. 
Currently available information suggests that 
pharmacologically furanylfentanyl is a narcotic opioid 
analgesic broadly similar to fentanyl.
Furanylfentanyl has been available in Europe since at 
least June 2015 and has been detected in 16 Member 
States and Norway. The detected quantities are 
relatively small; however, they should be considered in 
the context of the potency of furanylfentanyl. 
Furanylfentanyl is sold online as a ‘research chemical’, 
typically as a powder and as ready-to-use nasal sprays, 
in small and wholesale amounts. Limited information 
from seizures suggests that furanylfentanyl may have 
also been sold on the illicit opioid market.
Typically, the substance has been administered by nasal 
spray, orally and by nasal insufflation. Other routes of 
administration, including injecting, and vaping of 
e-liquids have also been reported. In the literature, 
smoking has also been reported as a route of 
administration. In addition, user reports indicate that 
blotters are also a possible route of administration. 
Concerns exist over novel ways of administering 
fentanils including furanylfentanyl. These include nasal 
sprays, e-liquids for vaping, and home-made 
transdermal patches. These may have the potential to 
make the use of fentanils easier and more socially 
acceptable. 
Eleven acute intoxications suspected to be due to 
furanylfentanyl have been reported in Europe. The 
clinical features were generally consistent with opioid-
like toxicity and included life-threatening effects. 
Clinical experience suggests that naloxone works as an 
antidote to poisoning caused by furanylfentanyl. 
Treatment may require repeated doses. 
Between November 2015 and February 2017, 23 deaths 
have been reported by 6 countries where furanylfentanyl 
was detected post-mortem. In the majority of cases 
other drugs were also detected with furanylfentanyl. In 
at least 10 deaths, furanylfentanyl was reported to be 
either the cause of death or to have contributed to death.
There have also been reports of severe non-fatal 
intoxications and deaths from the USA and Canada.
Due to the nature of furanylfentanyl both non-fatal 
intoxications and deaths are likely to be under-detected 
and under-reported.
Information from police seizures as well as 
investigations into deaths indicates that furanylfentanyl 
is available to and being used by high-risk drug users, 
including opioid users.
Accidental exposure to furanylfentanyl, as well as to 
other fentanils, poses a risk to law enforcement, 
emergency personnel, medical and forensic laboratory 
personnel, as well as to those in custodial settings and 
postal services. Specific risks and appropriate measures 
to reduce these risks should be identified and 
implemented. This may include appropriate protective 
equipment, training in resuscitation, and making 
naloxone readily available to relevant personnel in 
sufficient quantities in the event of poisonings.
There is no information to suggest the involvement of 
organised crime in the manufacture, distribution 
(trafficking) and supply within the European Union. There 
is limited information on the chemical precursors and the 
synthetic routes used to manufacture the furanylfentanyl 
detected within the European Union. Most of the synthetic 
routes are straightforward, make use of common 
laboratory equipment and readily available precursors, 
and require only basic knowledge of chemistry. 
Information from seizures suggests that some 
furanylfentanyl on the market in Europe has been 
produced by chemical companies based in China. In 
addition to importation, the seizure of an illicit laboratory 
in Europe in 2013 that was producing fentanils, that may 
have included furanylfentanyl, suggests that the 
production in Europe cannot be excluded. This case 
demonstrates the capability to manufacture fentanils 
exists within the European Union.
Furanylfentanyl has no recognised human or veterinary 
medical use in the European Union nor, it appears, 
elsewhere. There are no indications that furanylfentanyl 
may be used for any other purpose aside from as an 
analytical reference standard and in scientific research.
Furanylfentanyl is not listed for control in the Single 
Convention on Narcotic Drugs, 1961, nor in the 
Convention on Psychotropic Substances, 1971. 
Furanylfentanyl is not currently under assessment by the 
United Nations system. 
RISK ASSESSMENTS | Furanylfentanyl Risk Assessment Report
20/49
Ten Member States and Turkey control furanylfentanyl 
under drug control legislation and three Member States 
and Norway control furanylfentanyl under other 
legislation.
As for any new psychoactive substance, many of the 
questions related to furanylfentanyl that are posed by 
the lack of data on the risks to individual health, risks to 
public health, and social risks, could be answered 
through further research. Areas where additional 
information would be important include studies on: 
rationale for use, prevalence and patterns of use 
(including studies that examine user groups and risk 
behaviours); the market; chemical profiling; complete 
pharmacological profiling; metabolic pathways; 
behavioural effects; acute and chronic toxicity; the 
potential interaction between furanylfentanyl and other 
substances; the dependence and abuse potential; and 
the public health risks associated with its use.
The Committee notes that a decision to control 
furanylfentanyl has the potential to bring with it both 
intended and unintended consequences. Potential 
intended consequences include reduced levels of 
availability and ultimately use. This may reduce the 
health and social risks and consequences arising from 
the use of furanylfentanyl. It is important to recognise 
that a potential unintended consequence of control may 
be the manufacture and availability of other substances. 
Indeed, since furanylfentanyl was first detected at least 
eight new fentanils and a number of other new opioids 
that may replace furanylfentanyl have appeared / are 
already being sold on the drug market. The 
implementation of control measures may also lead to 
the criminalisation of those who continue to use this 
substance with the possible attendant risks of socio-
economic stigmatisation and marginalisation. 
Finally the Committee notes that it is important to 
continue to collect and disseminate accurate 
information on furanylfentanyl to users, practitioners, 
policy makers, decision makers and those who may be at 
risk of accidental exposure. An additional challenge in 
respect to reducing risk in users and potential users is 
the balance between providing information to prevent 
harm and the unintended consequences of 
communicating the risks of opioids. There is evidence 
that using terms to describe them as 'potent', 'strong', 
'deadly', and 'toxic' can lead some individuals to 
specifically seek out these substances. Such unintended 
promotion of the substances may also extend to former 
users and other groups. 
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ANNEX 1  
Technical report on N-phenyl-N-
[1-(2-phenylethyl)piperidin-4-yl]furan-
2-carboxamide (furanylfentanyl)
Report prepared by  
Simon Brandt (1), Simon Elliott (1), Helgi Valur 
Danielsson, Anabela Almeida, Ana Gallegos, Rita Jorge, 
Rachel Christie, Michael Evans-Brown, Roumen Sedefov.
Data sources
The information in this technical report is derived from:
 § data reported by the Member States, Turkey and 
Norway to the EMCDDA and Europol in accordance 
with Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of 
new psychoactive substances (2) (EMCDDA, 2017c); 
and, 
 § data collected through systematic searches of open 
source information, including the scientific and 
medical literature, patents, official reports, grey 
literature, Internet drug discussion forums and related 
websites, and online vendors selling furanylfentanyl.
Search strategy 
Literature searches used both chemical structure and 
text queries in online databases; searches were 
conducted in May 2017. The retrieved publications were 
then scanned for additional relevant references 
(snowballing technique).
Chemical structure-based searches were done in 
SciFinder® (American Chemical Society, Chemical 
Abstract Service) and Reaxys® (Elsevier) databases 
using both the exact structure of furanylfentanyl and a 
similarity search. Structural and text-based searches in 
SureChEMBL patent database retrieved three and two 
relevant hits, respectively. 
Textual searches were conducted online in PubMed 
(National Center for Biotechnology Information), Web of 
Science™ (Thomson Reuters), and in popular English-
language drug forums. The search term used were: 
(1) EMCDDA contract (ref. CT.17.SAT.0031.1.0).
(2) OJ L 127, 20.5.2005, p. 32. 
‘furanylfentanyl’, ‘furanyl-fentanyl’, ‘furanyl fentanyl’, 
‘Fu-F’, ‘fentanyl furanyl analogue’. 
The REACH registered substances database hosted by 
the European Chemicals Agency (ECHA) was searched 
using the CAS registry numbers listed below. The 
searches returned no hits.
Cursory, though repeated, inspections of English-
language Internet forums covered Bluelight, Drugs-
forum, ecstasydata.org, Erowid, Eve&Rave, Reddit and 
The Vespiary.
Additionally, the scientific networks of the authors were 
contacted to obtain information.
Section A. Physical, chemical, 
pharmaceutical and pharmacological 
information
A1. Physical, chemical, and pharmaceutical 
information
A1.1. Physical and chemical description
Chemical description and names
N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-
carboxamide (furanylfentanyl) is a furan-2-carboxamide 
derivative of N-phenyl-1-(2-phenylethyl)piperidin-4-
amine and structurally related to fentanyl, which is a 
propionamide (Table 1). Furanylfentanyl contains one 
basic nitrogen atom in the piperidine ring readily forming 
salts with organic or inorganic acids (3). 
(3) Note that ‘furanylfentanyl’ can refer to 2- and to 3-furanylfentanyl 
although in this report it refers only to the 2-isomer.
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Furanylfentanyl is a close structural relative of 
fentanyl (4,5), which is a fast and short-acting synthetic 
opioid that has been widely used in clinical practice as 
an adjunct to general anaesthesia during surgery and for 
postoperative pain management. Furanylfentanyl is also 
structurally related to acetylfentanyl and 
acryloylfentanyl, which were both the subject of an 
EMCDDA–Europol Joint Report in December 2015 and 
December 2016 following more than 30 deaths and 
more than 45 deaths, respectively (EMCDDA, 2016a, 
EMCDDA, 2017a). In February 2017, a risk assessment 
meeting on acryloylfentanyl was convened under the 
auspices of the Scientific Committee of the EMCDDA 
following the request by the Council of the European 
Union (EMCDDA, 2017b). 
Furanylfentanyl is known from the scientific literature only. 
Pharmacologically, furanylfentanyl is an opioid receptor 
agonist.
Fifteen fentanils are controlled under the United Nations 
Single Convention on Narcotic Drugs, 1961, as amended 
by the 1972 Protocol: 3-methylfentanyl, 
3-methylthiofentanyl, acetyl-alpha-methylfentanyl, 
alpha-methylfentanyl, alpha-methylthiofentanyl, beta-
hydroxy-3-methylfentanyl, beta-hydroxyfentanyl, 
para-fluorofentanyl, thiofentanyl, acetylfentanyl and 
butyrfentanyl are controlled under Schedule I and IV; 
alfentanil, fentanyl, sufentanil and remifentanil are 
controlled under Schedule I. The controls on 
acetylfentanyl and butyrfentanyl entered into force in 
2016 and 2017.
Names and other identifiers
Systematic International Union of Pure and Applied 
Chemistry (IUPAC) name: N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl]furan-2-carboxamide. 
Chemical Abstract name: N-phenyl-N-[1-(2-phenylethyl)-
4-piperidinyl]-2-furancarboxamide.
Other names: N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-
2-furamide; 2-furanoylfentanyl, 2-furanylfentanyl; 
N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-
carboxamide; 1-(2-phenylethyl)-4-(N-phenyl-2-furoylamido)
piperidine, N-(1-(2-phenylethyl)-4-piperidinyl)-
N-phenylfuran-2-carboxamide.
Commonly used names: furanylfentanyl, furanyl 
fentanyl, furanyl-fentanyl, 2-furanoylfentanyl, 
2-furanylfentanyl, despropionyl furanoylfentanyl, 
(4) http://www.emcdda.europe.eu/publications/drug-profiles/fentanyl 
(5) Fentanyl is included in Schedule I of the United Nations Single 
Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol.
despropionyl furanylfentanyl, furanylfenta and 
furanyylifentanyyli (Finnish). 
Chemical Abstract Service Registry Numbers 
(CAS RNs) (6)
  101345-66-8: free amine 
  101365-56-4: hydrochloride salt
PubChem SID: 313063233 (7)
IUPAC International Chemical Identifier Key (InCHI 
Key) (8): FZJVHWISUGFFQV-UHFFFAOYSA-N
SMILES (9): O=C(C1=CC=CO1)N(C2=CC=CC=C2)
C3CCN(CCC4=CC=CC=C4)CC3
Street names: Fu-F
Identification and analytical profile
Physical description 
Melting point: hydrochloride (HCl) salt: 235°C (dec.) 
(Huang et al., 1985, 1986) and 232.7°C (SWGDRUG, 
2016a). The hydrochloride salt has been described as a 
white powder (SWGDRUG, 2016a). Furanylfentanyl 
contains one basic nitrogen atom in the piperidine ring, 
which can readily form salts with organic or inorganic acids. 
Solubility data for furanylfentanyl base or its hydrochloride 
salt could not be found but an improved aqueous solubility 
is expected to occur with the hydrochloride salt. An impure 
sample of furanylfentanyl obtained from a test purchase 
was reported as soluble in dichloromethane and methanol 
and partially soluble in water. Whether the insoluble 
residues represented furanylfentanyl or impurities 
detected in the sample was not reported (Slovenian 
National Forensic Laboratory, 2015). The melting point for 
the positional furan-3-carboxamide isomer 
(3-furanylfentanyl, 3-Fu-F) (10) (oxalate) was reported as 
197°C (dec.) (Huang et al., 1985, 1986).
Chemical stability and typical reactions
Specific information about furanylfentanyl could not be 
identified.
(6) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division 
of the American Chemical Society to a specific, single chemical 
substance.
(7) https://pubchem.ncbi.nlm.nih.gov/compound/13653606
(8) InChI Key is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources.
(9) The simplified molecular-input line-entry system (SMILES) is a unique, 
non-proprietary structural identifier of chemical substances useful in 
electronic sources.
(10) Systematic name: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
furan-3-carboxamide. CAS RN (free amine): 101343-82-2; 101343-83-3 
(oxalate). 
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Analytical profile
The ultraviolet and visible spectrum of furanylfentanyl 
could not be found. Various spectroscopic and mass 
spectrometric data have been published as summarised 
in Table 2. Studies on the ability to differentiate between 
the 2- and 3-furanylfentanyl isomers could not be 
identified, although the infrared spectrum of the two 
isomers slightly differ (SWGDRUG, 2016a, 2016b). Mass 
spectral may not be sufficient to allow for unambiguous 
differentiation so the implementation of 
chromatographic and spectroscopic methods of analysis 
would be recommended. The aromatic region (6.0–
8.0 ppm) of 1H-NMR spectra of the two isomers are 
distinctly different (SWGDRUG, 2016a, 2016b).
Methods and chemical precursors used for 
the manufacture 
No information was reported to the EMCDDA about the 
chemical precursors or manufacturing methods used to 
make the furanylfentanyl which has been detected on 
the drug market in Europe. 
TABLE 1  
The molecular structure, molecular formula and molecular mass of fentanyl (left) and 2-furanylfentanyl (right).
Fentanyl Furanylfentanyl
O
N
N
O
N
N
O
C
22
H
28
N
2
O C
24
H
26
N
2
O
2
336.48 g/mol 374.48 g/mol
TABLE 2 
Chemical analysis data published for furanylfentanyl (a)
Techniques (b) Comment Reference
Melting point Characterisation of synthesised material. Huang et al. (1985, 1986)
GC-MS, FTIR-ATR, GC-sIR, HPLC-TOF, IC, 
1H and 13C NMR
Analytical characterisation of collected 
impure material.
Slovenian National Forensic Laboratory 
(2015)
Melting point, FTIR-ATR, GC-MS, 1H-NMR Analytical characterisation of DEA 
reference material.
SWGDRUG (2016a)
GC-MS Analytical characterisation of reference 
material.
Cayman Chemical Company (2016)
LC-QTOF-MS Analysis of human serum and urine 
samples.
Helander et al. (2016)
LC-QqQ-MS/MS Analysis of post-mortem human blood 
samples.
Mohr et al. (2016)
GC-MS Analysis of seized material. Casale et al. (2017)
LC-MS/MS Analysis furanylfentanyl and metabolites in 
human urine samples.
Goggin et al. (2017)
LC-QqQ-MS/MS Analysis of furanylfentanyl in human 
post-mortem femoral blood samples.
Guerrieri et al. (2017)
ELISA Method validation of a fentanyl ELISA assay 
in blood and urine. Furanylfentanyl showed 
significant cross-reactivity.
Tiscione and Wegner (2017)
LC-QTOF-MS/MS In vitro and in vivo metabolism study. Watanabe et al. (2017)
TD-DART-MS and IMS Characterisation of reference material. Sisco et al. (2017)
(a) As of 12 May 2017.
(b) GC: gas chromatography; MS: mass spectrometry; FTIR-ATR: Fourier transform infrared attenuated total reflection; sIR: solid state IR; HPLC: high 
performance liquid chromatography; TOF: time-of-flight; IC: ion chromatography; NMR: nuclear magnetic resonance spectroscopy; LC: liquid 
chromatography; QqQ: triple quadrupole; MS/MS: tandem MS; ELISA: enzyme-linked immunosorbent assay. TD-DART-MS: thermal desorption direct 
analysis in real time mass spectrometry; IMS: ion mobility spectrometry.
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Detailed information available with regards to route-
specific by-products produced during the synthesis of 
furanylfentanyl is not available.
Synthesis
The manufacture of furanylfentanyl relies on precursors 
and synthetic methods similar to those used for the 
manufacture of pharmaceutical fentanyl. Accordingly, 
methods developed for the multistep synthesis of 
fentanyl are applicable to furanylfentanyl but use a 
different acylating agent in the final acylation step. 
Correspondingly, the synthesis method of 
furanylfentanyl reported in the literature employed the 
acylation of the N-phenyl-1-(2-phenylethyl)piperidin-4-
amine (4-ANPP) intermediate, a precursor common to 
fentanyl and other fentanyl analogues, with furan-2-
carbonyl chloride (Figure 1). Preparation of the 
3-furanylfentanyl isomer involves the use of furan-3-
carbonyl chloride as the acylating agent (Huang et al., 
1985, Huang et al., 1986). 
Most of these synthetic procedures are straightforward 
but due to the high potency of fentanils there is a 
serious risk of severe poisoning following accidental 
exposure during its manufacture. Extreme care must 
be taken when carrying out the final synthetic step as 
well as when purifying and handling the substance. 
Likewise, accidental exposure of fentanils – such as 
skin contact, inhalation, or ingestion – pose a serious 
risk of poisoning to the public, law enforcement, 
emergency personnel, as well as medical and forensic 
laboratory personnel. In addition to exercising extreme 
caution when handling materials suspected to contain 
fentanils, personnel should be equipped with 
appropriate protective equipment. In addition, the 
antidote naloxone should be readily available to 
personnel in sufficient quantities; training in naloxone 
administration and resuscitation should also be 
available (CDC, 2013, DEA, 2016). 
The 4-ANPP precursor, as well as N-phenethyl-4-
piperidone (NPP; a pre-precursor), were scheduled on 
16 March 2017 and are listed in Table I of the United 
Nations Convention against Traffic in Narcotic Drugs 
and Psychotropic Substances, 1988 (CND, 2017). In 
2010 the U.S. Drug Enforcement Administration placed 
4-ANPP (named ANPP in the regulation) into Schedule II 
of the Controlled Substances Act in 2010 following its 
use as a precursor to make fentanyl in clandestine 
laboratories (DEA, 2010). Other routes developed for the 
production of fentanyl may also be used for the 
manufacture of furanylfentanyl. To date, there is no 
information on the actual method(s) used for the 
production of furanylfentanyl that has been detected 
in Europe.
Typical impurities encountered in seized and 
collected samples
There are no quantitative data available on the impurities 
detected in seized and collected samples reported to 
the EMCDDA. An impure furanylfentanyl sample 
obtained from a test purchase from an Internet vendor 
apparently based in China was reported to contain 
organic impurities. Analysis by gas chromatography 
mass spectrometry suggested the presence of furan-2-
carboxylic acid, which would be consistent with 
hydrolysed reagents used in the acylation step (furan-2-
carbonyl chloride and/or furan-2-carboxylic anhydride) 
(Slovenian National Forensic Laboratory, 2015). In 
addition, two countries (Germany and Spain) reported a 
powdered sample each containing ‘synthesis by-
products’ although these were not specified. 
Furanylfentanyl has also been identified in samples sold 
on the ‘deep web’ as methadone, carfentanil and 
FIGURE 1 
Final step of the synthesis of furanylfentanyl reported by Huang et al., (1985, 1986).
4-ANPP
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1,2-Dimethoxyethane
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fentanyl. Two samples purchased as the synthetic opioid 
U-47,700 (11) were confirmed to contain furanylfentanyl. 
Other substances detected in seized powder samples, 
and reported by various countries include: 
4-fluoroisobutyrylfentanyl (4F-iBF); ortho-fluorofentanyl 
(or 2-fluorofentanyl), cocaine and mannitol; heroin; 
inositol; lactose; mannitol; and paracetamol and caffeine 
and 4-ANPP. Two liquid samples obtained from ‘darknet’ 
vendors were reported to also contain glycerol (see 
section C). 
In the United States, levamisole and dipyrone 
(metamizole) (12) have been identified in furanylfentanyl 
samples (Logan, 2017).
A1.2. Physical/pharmaceutical form 
Data from seizures and collected samples reported to 
the EMCDDA indicate furanylfentanyl has typically been 
detected in powders, liquids, and occasionally in tablets 
and in green ‘herbal’ material. Some of the liquids have 
been detected as commercially prepared ready-to-use 
nasal sprays (EMCDDA, 2017c) and as e-liquids for 
vaping. Given the high potency associated with fentanyl 
analogues, the existence of blotters cannot be fully 
excluded (13). A drug formulation intended for parenteral 
or intravenous analgesic administration of a range of 
fentanyl analogues has been suggested in a patent by 
Huang et al. (1985, 1986) but specific details on 
furanylfentanyl have not been described.
A1.3. Route of administration and dosage 
Furanylfentanyl, similar to other opioids, can be 
administered orally as a powder (including in capsules), 
as tablets, or as a solution (using nasal sprays or by 
insufflation of a powder); it can also be administered 
intranasally or sublingually via a spray; inhaled by smoking 
or vaporizing; and, administered by injection (intravenous 
and intramuscular). Furanylfentanyl has also been offered 
for sale in the form of propylene glycol/glycerol solutions 
(e.g. 30 mg/mL), presumably intended for vaporisation as 
an e-liquid in electronic cigarettes (‘vaping’). 
Data reported to the EMCDDA regarding acute 
intoxications suspected to involve furanylfentanyl 
(section D1.2) suggests that furanylfentanyl was 
(11) Systematic name: 3,4-Dichloro-N-[(1R,2R)-2-(dimethylamino)
cyclohexyl]-N-methylbenzamide.
(12) Dipyrone (or metamizole (INN)), is a phenylpyrazolone analgesic-
antipyretic and used as a cutting agent by Mexican drug suppliers 
(Logan, 2017).
(13) https://www.youtube.com/watch?v=qDPE0EYe5Ss (last accessed 
07 May 2017)
administered nasally (by nasal spray), by intramuscular 
injection, snorted as a powder or administered orally. 
E-liquids containing furanylfentanyl have been reported 
by France in collected samples test-purchased from 
vendors on darknet marketplaces. Poland reported 
several seizures of branded ‘legal-high’-type products 
which contained furanylfentanyl in ‘herbal’ material. It is 
not known if these products were intended to be smoked 
or taken orally. 
These routes of administration are similar to those 
reported with other fentanils. Of note is the apparent 
recent popularity of using ready-to-use or home-made 
nasal sprays containing solutions for the administration 
of furanylfentanyl. This finding extends to the use of 
other fentanils that have appeared in Europe in the past 
few years, including acryloylfentanyl (EMCDDA, 2017a; 
EMCDDA, 2017b).
Discussions on user websites include the descriptions of 
blotters (YouTube, 2017 (13)), ingestion by vaping (Reddit, 
2017 (14)), intravenous injection (Erowid, 2017 (15)), and 
preparations of solutions for nasal spray application 
(Bluelight, 2017 (16); Drugs-Forum, 2017 (17)).
Dosage 
Limited information is available regarding the dose and 
the dose regimens of furanylfentanyl. From this it is not 
possible to discern the ‘typical’ dosages administered by 
users. While a range of doses have been reported, these 
appear to differ depending on factors such as the route 
of administration, the tolerance of the users, the use of 
other drugs, and the desired effects. Given the 
difficulties of collecting such data the information below 
should be used with caution.
Limited data reported to the EMCDDA regarding acute 
intoxications suspected to involve furanylfentanyl 
suggests that a range of doses may be used. In 2 cases 
the amount of furanylfentanyl used was reported as 
5 mg nasally (1 case) and 50 mg orally (1 case). The 
information was either unknown or not reported in the 
remaining 8 cases. 
Some additional information on dosage is provided in 
user websites. As already highlighted, the assessment of 
such reports is problematic not least because the purity, 
amount and/or composition of the substance ingested 
(14) https://www.reddit.com/user/Furanylfentanyl/ (last accessed 
07 May 2017)
(15) https://erowid.org/experiences/exp.php?ID=109044 (last accessed 
07 May 2017)
(16) http://www.bluelight.org/vb/threads/755118-Novel-opioid-
Furanylfentanyl (last accessed 07 May 2017)
(17) https://drugs-forum.com/threads/creating-a-fu-f-fent-analog-nasal-
spray.281744/ (last accessed 07 May 2017)
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are typically not known by the user. Moreover, the actual 
composition of the substance may differ over time and 
different geographical areas. 
One website claiming to provide information on drugs and 
harm reduction lists the following dosage information 
about oral administration and ‘insufflation’. Oral: ‘light’ 
300–500 µg; ‘common’: 500–900 µg; ‘strong’ 
900–1600 µg and above. Insufflation: ‘light’ 200–400 µg; 
‘common’ 400–800 µg; ‘strong’ 800–600 µg and above 
(TripSit, 2017 (18)). 
Information about the dose/volumes delivered by 
ready-to-use or home-made nasal sprays containing 
furanylfentanyl could not be identified.
A2. Pharmacology, including pharmacodynamics 
and pharmacokinetics
Pharmacodynamics
In vitro studies
The currently available data generated via the Drug 
Enforcement Administration–Veterans Affairs (DEA-VA) 
Interagency Agreement (DEA, 2017) suggest that 
furanylfentanyl binds to the µ-opioid receptor (MOR) 
with high selectivity (K
i
 = 0.0279 nM) over the κ- and 
δ-opioid receptors (KOR and DOR) with K
i
 values of 
59.2 nM and 54 nM, respectively (Table 2) (19) 
(DEA, 2017).
Table 3 provides a summary of additional binding and 
functional activity data (adapted from DEA (2017)) that 
illustrate that furanylfentanyl (EC
50
 = 2.52 nM, [35S]
GTPγS binding assay, E
max
 = 55.5 %) functioned as a 
MOR agonist more potent than morphine 
(EC
50
 = 31.0 nM, [35S]GTPγS binding assay, E
max
 = 
83.3 %) and fentanyl (EC
50
 = 17.9 nM, E
max
 = 81.2 %) 
although it functioned less efficaciously than morphine 
or fentanyl, the two comparator drugs (compare 
E
max
 values). Furanylfentanyl also showed appreciable 
affinity toward KOR but showed only very low efficacy 
as an agonist (E
max
 = 24.9 %) compared to 
U-50,488H (20) (E
max
 = 81.2 %), morphine 
(E
max
 = 86.8 %) and fentanyl (E
max
 = 72.9 %), 
respectively. Furanylfentanyl was functionally inactive 
(18) http://drugs.tripsit.me/furanylfentanyl (last accessed 07 May 2017)
(19) K
i
 represents the equilibrium inhibition constant for the test drug 
displacing the radioligand.
(20) According to Von Voigtlander and Lewis (1982), U-50,488H refers to 
the methanesulfonate hydrate salt whereas U-50,488E refers to the 
monohydrochloride hemihydrate salt.
at DOR but displayed a higher affinity (K
i
 = 54 nM, [3H]
DPDPE) compared to morphine (K
i
 = 111 nM, [3H]
DPDPE) and fentanyl (K
i
 = 242 nM, [3H]DPDPE) 
(DEA, 2017).
These receptor studies have established furanylfentanyl 
to be potent agonist of opioid receptor types MOR and 
DOR. It is not known, however, whether this MOR agonist 
effect, which is responsible – among other physiological 
effects – for respiratory depression, would translate to 
high toxicity in vivo.
Animal studies
Results from animal studies could only be identified in 
one study. Following intravenous administration (tail 
vein), furanylfentanyl displayed antinociceptive effects 
using the mouse hot plate test (21). The ED
50
 value (22) 
was determined as 0.02 mg/kg although data for 
comparator substances, such as morphine and 
fentanyl, were not reported. Evaluation of the 
3-furanylfentanyl isomer revealed a ~4-fold drop in 
potency (ED
50
 = 0.076 mg/kg) (Huang et al., 1985, 
1986). The patent gives an ED
50
 of 0.0077 mg/kg for 
ocfentanil (1-(2-phenylethyl)-4-[N-(2-fluorophenyl)
methoxyacetamido]piperidinium oxalate), another 
synthetic opioid reported to EU Early Warning System 
and notified as a new psychoactive substance in 2013 
(EMCDDA & Europol 2014).
A separate study published by Bagley et al. (1989), 
reporting on the analgesic properties of a range 
4-(heteroanilido)piperidines, identified an ED
50
 value of 
0.018 mg/kg for fentanyl in the mouse hot plate test 
(55°C instead of 58°C by Huang et al. (1985, 1986)), 
which indicates that fentanyl and furanylfentanyl have 
comparable analgesic potency in this animal assay. 
Schneider and Brune (1986) reported that fentanyl 
(ED
50
 = 0.015 mg/kg) was over 230-fold more potent 
than morphine (ED
50
 = 3.5 mg/kg) and > 1,300-fold 
more potent than pethidine (ED
50
 = 20.0 mg/kg) in the 
mouse hot plate test. In comparison, acryloylfentanyl (23) 
(ED
50
 = 0.082 mg/kg), recently being subject to an 
(21) Tests the ability of antinociceptive agents to inhibit paw lick responses 
of mice placed in contact with a heated surface. In the study reported 
by Huang et al. (1985, 1986), the temperature was set at 58°C. 
(22) The dose at which 50% of test animals meet the criteria for the 
analgesic response. The median effective dose (ED
50
) can be 
calculated by measuring the prolongation of latency times of a 
response to pain after administration of the test substance at various 
doses as compared to untreated control.
(23) Systematic name: N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
prop-2-enamide. 
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EMCDDA risk assessment, exhibited 76 % of the 
potency of fentanyl (ED
50
 = 0.062 mg/kg) whereas 
morphine (ED
50
 = 13.9 mg/kg) only showed 4.5 % of 
fentanyl’s antinociceptive potency in the mouse hot 
plate test (Zhu et al., 1981, cited in EMCDDA, 2017b). 
Furanoyl analogues of 3-methylfentanyl have also been 
pharmacologically characterised and their activity in 
vivo and in vitro were compared to morphine and 
fentanyl using the mouse hot plate test (55°C) (Lalinde 
et al., 1990). The ED
50
 values for the antinociceptive 
activities of the cis- and trans-isomers of 3-methyl-
furanylfentanyl were 0.005 and 0.082 mg/kg, 
respectively; the relevant ED
50
 values for morphine and 
fentanyl were 7.3 and 0.018 mg/kg, respectively. The K
i
 
values in the [3H]naloxone binding inhibitory assay for 
cis- and trans-methyl-furanylfentanyl, morphine and 
fentanyl were 0.30, 0.40, 2.1 and 2.16 nM, respectively 
(Lalinde et al., 1990).
Pharmacokinetics
Available clinical data suggest that furanylfentanyl is 
detectable as the parent drug in a variety of biological 
matrices such as urine (Goggin et al., 2017, Watanabe et 
al., 2017), post-mortem blood (Guerrieri et al., 2017) and 
serum (Helander et al., 2016). A recent in vitro 
investigation using human hepatocytes revealed the 
detection of 14 furanylfentanyl metabolites (Watanabe 
et al., 2017) (Figure 2) and a comparison with human 
post-mortem urine samples suggested the identification 
of nine metabolites (D1, D2, D4–D8, D10, D14) with 
4-ANPP (metabolite D14), dihydroxy-dihydrofuranyl-
fentanyl (D10) and D7 being particularly abundant. 
4-ANPP might also be detectable in biofluids when 
present as a synthesis by-product. In contrast to what 
was found after incubation with hepatocytes, the 
desphenethyl metabolite D6 (‘norfuranylfentanyl’ (24)) 
(24) Systematic name: N-Phenyl-N-(piperidin-4-yl)furan-2-carboxamide.
TABLE 3  
Opioid receptor binding data of furanylfentanyl (modified from DEA (2017)) (a)
MOR Furanylfentanyl DAMGO Morphine Fentanyl Naltrexone
[3H]DAMGO binding K
i
 (nM)
IC
50
 (nM)
0.0279 ± 0.0080
0.192 ± 0.058
0.1313 ± 0.0050
–
0.213 ± 0.019
–
0.150 ± 0.030
–
0.0793 ± 0.0042
–
Hill coefficient -0.55 ± 0.04 -0.89 ± 0.06 -0.95 ± 0.02 -0.72 ± 0.07 -0.81 ± 0.36
[35S]GTPγS binding Furanylfentanyl DAMGO Morphine Fentanyl
Stimulation EC
50
 (nM) 2.52 ± 0.46 21.4 ± 4.2 31.0 ± 8.2 17.9 ± 4.3 –
Maximal stimulation (%)* 55.5 ± 4.3 96.8 ± 1.9 83.3 ± 5.5 81.2 ± 7.4 –
DOR Furanylfentanyl DPDPE-OH Morphine Fentanyl Naltrexone
[3H]DPDPE binding K
i
 (nM)
IC
50
 (nM)
54 ± 15
88 ± 26
2.96 ± 0.57
–
111 ± 14
–
242 ± 20
–
14.2 ± 3.1
–
Hill coefficient -0.70 ± 0.07 -0.94 ± 0.10 -0.96 ± 0.02 -0.93 ± 0.09 -1.03 ± 0.12
[35S]GTPγS binding Furanylfentanyl DPDPE-OH Morphine Fentanyl
Stimulation EC
50
 (nM) >10 μM 7.22 ± 0.38 870 ± 140 1,190 ± 140 –
Maximal stimulation (%)* 0 100.97 ± 0.97 77.3 ± 2.3 58.0 ± 4.2 –
KOR Furanylfentanyl U-50,488H Morphine Fentanyl Nor-BNI
[3H]U-69,593 binding K
i
 (nM)
IC
50
 (nM)
59.2 ± 6.4
130 ± 14
0.155 ± 0.048
–
27.9 ± 2.7
–
194 ± 20
–
0.42 ± 0.21
–
Hill coefficient -0.85 ± 0.06 -0.70 ± 0.03 -0.98 ± 0.06 -1.19 ± 0.17 -1.11 ± 0.23
[35S]GTPγS binding Furanylfentanyl U-50,488H Morphine Fentanyl –
Stimulation EC
50
 (nM) 60 ± 25 1.15 ± 0.22 83 ± 23 362 ± 47 –
Maximal stimulation (%)* 24.9 ± 1.5 93.6 ± 2.2 86.8 ± 6.0 72.9 ± 3.2 –
(a) In receptor binding experiments, transfected Chinese hamster ovary (CHO) cells expressing human δ- and κ-opioid receptors and rat μ-opioid 
receptors were used. Experimental details for functional activity studies are not reported. DOR: delta opioid receptor; KOR: kappa opioid receptor; MOR: 
mu opioid receptor; DAMGO: Tyr-Ala-Gly-Nme-Phe-Gly-ol, DPDPE: Tyr-Pen-Gly-Phe-Pen [disulfide bridge: 2-5]; U-69,593: (+)-(5α,7α,8β)-N-Methyl-N-[7-
(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide; U-50,488H: trans-(±)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]
benzeneacetamide methanesulfonate salt; Nor-BNI: norbinaltorphimine; U-69,593: (+)-(5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]
dec-8-yl]-benzeneacetamide. SEM: standard error of the mean.
Numbers represent the means ± SEM from at least three independent experiments, each conducted with duplicate determinations. A Hill coefficient 
other than one suggests complex interactions with binding sites. Standard compounds are the agonists DPDPE (delta), U50,488H (kappa) and DAMGO 
(mu) and the antagonists naltrexone (delta and mu) and nor-BNI (kappa).
* Maximal stimulation by test compound is normalized to the maximal stimulation by DPDPE (delta), U50,488H (kappa) or DAMGO (mu) above basal. 
Negative values indicate inhibition of basal [35S]GTPγS binding.
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seemed to have played a comparatively minor role in its 
detectability in human urine samples (Watanabe et al., 
2017). A metabolism study involving butyrfentanyl (25) 
revealed that the corresponding norbutyrfentanyl 
species (26) was abundantly formed under in vitro 
conditions using pooled human liver microsomes 
(predominantly catalyzed by CYP3A4 but also CYP1A2, 
2C8, and 2C19). The analysis of a post-mortem blood 
sample suggested a comparatively minor abundance of 
this; however, the detection of clarithromycin, a known 
potent CYP3A4 inhibitor, was also reported, which might 
have impacted on the formation of the metabolite. 
Post-mortem redistribution and/or contributions from 
variations in enzyme phenotypes might also have 
accounted for this observation (Steuer et al., 2016). 
Given that some of the detected metabolites (e.g. 
4-ANPP, or D14, and its hydroxylated derivatives) are not 
specific for furanylfentanyl, a suggested target for 
specific furanylfentanyl-related intoxication would have 
to include a species carrying the biotransformation 
products associated with the furan ring, such as D10 
and/or D7 (Watanabe et al., 2017). While specific 
information for furanylfentanyl is not available, it should 
be noted that furanyl moieties can potentially lead to the 
formation of unstable and reactive metabolites which 
are known to cause hepatic and renal necrosis (Peterson, 
2013) In addition to the unmodified molecule, 4-ANPP, 
(25) Systematic name: N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]
butanamide.
(26) Systematic name: N-Phenyl-N-(piperidin-4-yl)butanamide. 
its sulfate and the dihydrodiol metabolite (and 
occasionally norfuranylfentanyl) were also detected in 
human urine samples obtained from pain management 
programs of individuals who tested positive for 
6-acetylmorphine (Goggin et al., 2017).
In 8 post-mortem cases in which furanylfentanyl was 
detected, 4-ANPP was reported in 5 aorta blood 
samples (Mohr et al., 2016).
There is some information on the biological activity of 
4-ANPP using intact guinea pig ileum preparations. 
Compared to fentanyl (IC
50
 = 4 nM), 4-ANPP was 
significantly less potent in inhibiting contractions of ileum 
segments induced by coaxial electrical stimulation (IC
50
 = 
12,000 nM). The IC
50
 value determined for morphine was 
50 nM (Schneider and Brune, 1986). Two metabolites 
showed activity in this study: the phenolic derivative 
hydroxylated at the 4-position of the phenylethyl moiety 
of fentanyl (27), the activity (IC
50
 = 240 nM) of which was 
found to lie between morphine and pethidine (IC
50
 = 
1,300 nM), and the benzylic alcohol type derivative of 
fentanyl which had an IC
50
 value of 50 nM. This latter 
biotransformation product is related to furanylfentanyl 
metabolite D11 (Figure 2). Further studies are required to 
assess the formation of the corresponding furanylfentanyl 
metabolite and whether this substance would exert 
biological activity.
(27) Systematic name: N-{1-[2-(4-hydroxyphenyl)ethyl]piperidin-4-yl}-N-
phenylpropionamide.
FIGURE 2  
Suggested metabolic pathway of furanylfentanyl based on incubation with human hepatocytes and detection in 
human urine samples (Watanabe et al., 2017). Enclosed metabolites: major metabolites detected in hydrolysed 
human urine samples; italicized metabolites: only found either under in vitro or in vivo conditions.
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Inter-individual genetic variability in metabolising 
enzymes
For fentanyl, oxidative dealkylation by hepatic CYP3A4 
and by CYP3A5 isoenzymes to norfentanyl has been 
demonstrated (Guitton et al., 1997, Jin et al., 2005, 
Labroo et al., 1997). The variation of the expression of 
the genes coding for these CYP3A isoenzymes among 
populations might be of clinical significance (Meyer and 
Maurer, 2011) but further studies are needed to address 
the toxicological consequences of such polymorphisms.
Interactions with other substances and other 
interactions 
Specific information about furanylfentanyl could not be 
identified although it seems conceivable that 
interactions observed with fentanyl (EMCDDA, 2017b, 
Preston, 2016) might equally apply. For example, should 
furanylfentanyl undergo oxidative dealkylation by 
hepatic CYP3A4 and by CYP3A5 isoenzymes then the 
use of this substance with inhibitors of these 
isoenzymes, such as clarithromycin, erythromycin, 
fluconazole, grapefruit juice, indinavir, itraconazole, 
ketoconazole, nefazodone, ritonavir, saquinavir, 
suboxone, verapamil) (28) may result in increased plasma 
concentration of furanylfentanyl. This could increase the 
risk of poisoning, including potentially fatal respiratory 
depression. 
The concomitant use of other central nervous system 
(CNS) depressants, including other opioids, sedatives/
hypnotics (such as the benzodiazepines and the 
z-drugs), ethanol, gabapentinoids (pregabalin and 
gabapentin), tranquillisers, sedating anti-histamines, and 
skeletal muscle relaxants may produce additive 
depressant effects. 
The use of fentanyl with serotoninergic agents, such as 
selective serotonin re-uptake Inhibitors (SSRIs) (the 
most commonly prescribed antidepressants) or 
serotonin norepinephrine re-uptake inhibitors (SNRIs) or 
monoamine oxidase inhibitors (MAOIs) has been 
associated with a serotonin syndrome, a potentially 
life-threatening condition. This association is likely to 
extend to illicit drugs, which act on the serotonergic 
system. It is not known if this association is also seen 
with furanylfentanyl.
(28) For a more comprehensive list of drug interactions with fentanyl, see, 
for example, http://www.ema.europa.eu/ema/index.jsp?curl=pages/
medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&-
source=homeMedSearch&keyword=fentanyl&category=human&is-
NewQuery=true
Effects on ability to drive and operate machines
No studies of the effects of furanylfentanyl on the ability 
to drive and operate machines have been performed. 
However, it is well established that opioid analgesics, 
such as fentanyl, impair the mental and physical ability 
required to drive and operate machines. This effect is 
likely to extend to furanylfentanyl. 
A3. Psychological and behavioural effects
Information on the psychological and behavioural 
effects of furanylfentanyl is limited to serious adverse 
events reported to the EMCDDA and self-reported 
experiences from user websites. From the limited 
data available, it appears that the psychoactivity of 
furanylfentanyl shares some similarities with other 
opioid analgesics such as fentanyl and heroin, including 
relaxation and sedation. 
One user described a steep dose-response curve 
with a very small gap between ‘unnoticeable’ effects 
(intravenous administration) and severe adverse 
effects (29). Some user reports also suggest a rapid 
development of tolerance.
A4. Legitimate uses of the product 
Furanylfentanyl is used as an analytical reference 
material in clinical and forensic case work/investigations 
as well as scientific research. There is currently no 
information that suggests furanylfentanyl is used for 
other legitimate purposes.
There are no reported uses of furanylfentanyl as a 
component in industrial, cosmetic or agricultural 
products. In addition, a search of the Registration, 
Evaluation, Authorisation and Restriction of Chemicals 
(REACH) registered substances database hosted by 
the European Chemicals Agency (ECHA) using the CAS 
Registry Number returned no results.
There is no marketing authorisation (existing, ongoing or 
suspended) for furanylfentanyl neither in the European 
Union nor in the Member States that responded to the 
request for information from the European Medicines 
Agency, which was undertaken as part of the Joint 
Report process (EMCDDA, 2017c).
(29) https://erowid.org/experiences/exp.php?ID=109044 (last accessed 
16 April 2017) 
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There is no information to suggest that furanylfentanyl 
is currently used in the manufacture of a medicinal 
product in the European Union. However, in the absence 
of a database on the synthetic routes of all medicinal 
products it is not possible to confirm whether or not 
furanylfentanyl is currently used in the manufacture of a 
medicinal product. 
Section B. Dependence and abuse 
potential
B1. Animal data 
No studies were identified that have investigated the 
dependence and/or abuse potential of furanylfentanyl in 
animal models.
B2. Human data 
No studies were identified that have investigated the 
dependence and/or abuse potential of furanylfentanyl in 
humans. 
The limited information available from user websites 
suggests that some users of furanylfentanyl report an 
urge to re-dose, an apparent ‘rapid’ development of 
tolerance, as well as symptoms suggestive of withdrawal.
While no specific data exists for furanylfentanyl, it is well 
established that opioid analgesics such as fentanyl have 
an abuse liability and can induce tolerance and 
dependence. Research is required in order to examine 
these effects with furanylfentanyl. 
Section C. Prevalence of use
Information from seizures, collected and 
biological samples
Furanylfentanyl was formally notified on 3 November 2015 
by the EMCDDA on behalf of the Finnish national focal 
point, in accordance with Article 4 of the Council Decision. 
The Reporting Form details a seizure of 0.2 g of pale brown 
powder that was seized on 29 June 2015 by customs in 
incoming mail arriving from Poland. The identification and 
analytical characterisation was initially based on GC-MS 
and LC-MS analysis, followed by NMR confirmation 
performed by the Swedish National Forensic Centre.
Although the first official reported detection of 
furanylfentanyl in Europe was from June 2015, an illicit 
laboratory was seized in Europe in 2013 that was 
producing fentanils which may have included 
furanylfentanyl (30), suggests that the production in 
Europe cannot be excluded. This case demonstrates the 
capability to manufacture fentanils exists within the 
European Union.
Since then, a total of 16 Member States and Norway 
have reported detections of furanylfentanyl (31) 
(EMCDDA, 2017c).
Information from seizures
A total of 13 Member States (Austria, Belgium, Cyprus, 
Czech Republic, Denmark, Estonia, Finland, Germany, 
Hungary, Luxembourg, Poland, Sweden and the United 
Kingdom) and Norway reported seizures (32) of 
furanylfentanyl to the EMCDDA and/or Europol. 
Information reported to the EMCDDA and Europol 
indicates that 143 seizures of furanylfentanyl have been 
reported by: Austria (5), Belgium (7), Cyprus (1), Czech 
Republic (1), Denmark (3), Estonia (10), Finland (20), 
Germany (16), Hungary (1), Luxembourg (2), Norway (1), 
Poland (18), Sweden (52) and the United Kingdom (6). 
Most of the seizures were made during 2016 and 2017 
by Police or Customs. Many of the seizures appear to 
have been made at street-level. 
Physical forms seized included: powders (92 seizures; 
amounting to a total weight of 1035.9 g), liquids (30; 
1558.9 mL), herbal material (12; 5.75 g) and tablets (3; 
45 tablets). In 6 of the cases the physical form seized 
was not specified. 
The detected quantities are relatively small; however, 
they should be considered in the context of the high 
potency of furanylfentanyl.
(30) Preliminary analysis by LC-MS/MS revealed the presence of 
furanylfentanyl and traces of 4-ANPP. NMR was not performed.
(31) ‘Detections’ is an all-encompassing term and may include seizures 
and/or collected and/or biological samples that are analytically 
confirmed. Seizure means a substance available (seized) through law 
enforcement activities (police, customs, border guards, etc.). 
Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and 
research purposes. Biological samples are those from human body 
fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.) 
(32) Many ‘seizures’ relate to individual case-level data, however, some data 
provided to the EMCDDA are aggregated at the country level. Data is 
drawn from the Joint Report Questionnaires and data provided in the 
bi-annual data gathering (EU EWS progress and final reports) and from 
individual Reporting forms submitted on an ad hoc basis.
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Powders
 § 92 seizures in powder form amounting to a total weight 
of 1035.9 g were reported by 13 Member States and 
Norway.
 § The largest single seizure made by police, amounting 
to 276 g, took place in the United Kingdom in 
September 2016. In this case, related to a darknet 
vendor supplying fentanils, 5 packages weighing from 
640 mg to 219 g were seized. The vendor claimed to 
be selling mixtures of butyrfentanyl with mannitol, but 
analysis of 5 samples that were reported to the 
EMCDDA were found to contain furanylfentanyl, with 
three of those also containing other substances. The 
seized samples included a package of white powder 
that contained furanylfentanyl, ortho-fluorofentanyl, 
cocaine (less than 1 %) and mannitol.
 § The largest single seizure made by customs amounted 
to 101 g and took place in Belgium in October 2016 at 
Bierset Airport. The final destination was Spain.
 § In powder samples, furanylfentanyl has been detected 
in mixtures with other opioids such as heroin, U-47,700, 
fentanyl, 2-fluorofentanyl, 4F-isobutyrfentanyl (4F-iBF) 
and carfentanil. It has also been detected with cocaine, 
caffeine, paracetamol, and sugars/sugar alcohols 
(lactose, mannitol, inositol).
 § Seized powders have typically been described as 
white; in 1 case, a beige powder was reported 
(Norway).
 § In a seizure of powder reported by Germany, the 
powder was found in a plastic bag and labelled as 
‘2ha-IF’.
 § Information on the purity of powders containing 
furanylfentanyl was available for 5 samples reported 
by Finland (4) and Belgium (1). Two of the samples 
from Finland were found to contain 100 % pure 
furanylfentanyl; one was found to contain 8 % 
furanylfentanyl, 48 % U-47,700, and paracetamol (not 
quantified); while the remaining sample contained 
60 % furanylfentanyl and 4.5 % U-47,700. The sample 
reported by Belgium contained a mixture of 
furanylfentanyl and 4F-iBF (1 to 5 parts).
Liquids
 § 30 seizures of furanylfentanyl in liquid form 
amounting to a total of 1558.9 mL were reported by 
3 Member States: Austria (2), Finland (3) and 
Sweden (25).
 § The largest seizure of furanylfentanyl in liquid form 
amounted to 974.5 mL and was made by Finnish 
police in November 2016. In this case, a total of 16 
samples of liquid and 4 samples of powder containing 
furanylfentanyl were seized.
 § 25 of the samples were in the form of ‘nasal sprays’, 
8 were reported as a ‘liquid in a bottle’ and in 1 case 
the liquid was detected in a syringe.
 § The colour of the seized liquid was only reported in 
1 case where it was described as a ‘yellow liquid in 
spraybottle’ (Sweden).
 § Furanylfentanyl was the only reported substance in 
29 seizures, and in 11 out of the 16 samples from the 
large seizure reported in Finland (details above).
 § Quantitative data on purity was provided for 15 samples 
reported by Finland. Furanylfentanyl was found in 
concentrations ranging from 1.1 to 3.2 mg/mL (mean: 
1.9, median: 1.8). In 5 of the samples, U-47,700 was also 
detected with furanylfentanyl, the relative concentrations 
of furanylfentanyl/U-47,700 in 4 of these cases were: 
1.9/0.1; 1.8/0.09; 1.1/0.06 and 1.2/18 mg/mL.
Herbal material
 § 12 seizures where furanylfentanyl was detected in 
herbal material, were reported by Poland, amounting 
to 5.75 g. In 5 of the seizures, the brand name 
‘Talizman’ was used on the packaging (33).
Tablets
 § 3 seizures of furanylfentanyl in tablet form were 
reported by Swedish police, with a total amount of 
45 tablets seized.
Information from collected samples
A total of 16 collected samples were reported to the 
EMCDDA by 4 Member States: France (7), Germany (2), 
Slovenia (1) and Spain (6).
 § 14 of the seizures were of powders, while the 
remaining 2 were in liquid form.
 § the total amount of powder collected was 2.03 g but 
in most cases the quantity collected was not reported.
 § 4 of the collected samples reported by France were 
purchases from the darknet: 2 liquids, which were 
found to contain furanylfentanyl mixed with glycerol, 
were presented as an e-liquid for vaping in an 
electronic cigarette (1) and as a nasal spray (1); and 
2 powders, 1 bought as U-47,700 and 1 which 
originated in China.
 § 5 of the collected samples were sold and/or 
purchased as U-47,700 (2), fentanyl (1), carfentanil (1) 
and methadone (1), respectively.
One of the samples was collected from a user that lost 
consciousness after snorting a white powder. The user 
was discharged after treatment.
(33) ‘Talizman motocyklisty’, ‘Talizman 0,5g-Ziel’, ‘Talizman 1,0g – Ziel’, 
‘Talizman GT 0,5g-Ziel’ and ‘Talizman GT 1,0g – Ziel’.
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Information from biological samples
A total of 24 detections where furanylfentanyl was 
analytically confirmed in biological samples were 
reported by 5 Member States and Norway.
These related to: 23 deaths ((Estonia (4), Finland (1), 
Germany (4), Sweden (12), United Kingdom (1)) and 
Norway (1) and 1 non-fatal intoxication (Sweden).
Availability, supply, price
Data from seizures, collected samples and acute 
intoxications suspected to involve furanylfentanyl 
suggests that the substance is sold as a powder. It is 
also sold as ready-to-use nasal sprays. Furanylfentanyl 
is sold online and is available in small and wholesale 
amounts. 
Furanylfentanyl has been detected in mixture with: 
U-47,700 (in 2 powders and 5 liquids reported by 
Finland); fentanyl and carfentanil (in some powders 
reported by Estonia); 4F-iBF (1 case, Germany); heroin 
(1, the United Kingdom); 2-fluorofentanyl, cocaine and 
mannitol (1, UK); caffeine (1, Sweden); inositol (1, UK); 
lactose (1, UK); glycerol (2, France); sorbitol (1, France); 
and unspecified synthesis by-products (see 
Section A1.1).
Information on production
Information available on the production of 
furanylfentanyl in Europe is limited to one case. 
Although the first official reported detection of 
furanylfentanyl in Europe was from June 2015, an illicit 
laboratory was seized in Europe in 2013 that was 
producing fentanils which may have included 
furanylfentanyl (34). This suggests that the production in 
Europe cannot be excluded.
Information on trafficking
In 7 seizures made by Belgian customs at Bierset airport 
the country of destination of the seizure (all in powder 
form) was: Spain (1 seizure amounting to 101 g), 
Germany (3), France (1), the Netherlands (1) and 
Slovenia (1). Information on the origin of the shipments 
is not available.
(34) Preliminary analysis by LC-MS/MS revealed the presence of 
furanylfentanyl and traces of 4-ANPP. NMR was not performed.
In the cases where the origin of the seizures/collected 
samples reported to the EMCDDA was known, the 
country of origin indicated was: Poland (in at least 
20 seizures of powder made in Estonia (10) and 
Finland (10)); the United Kingdom (1 seizure of powder, 
reported by Cyprus) and China (1 seizure of 11 g of 
powder, reported by Hungary). 
Information reported to Europol on the trafficking routes 
is limited to seizure cases reported (EMCDDA, 2017c). In 
all cases where the country of origin was known, China 
was indicated (Estonia, Germany, Luxembourg and 
Sweden). Although there is limited information available, 
it also appears that furanylfentanyl trafficked into the 
United States is produced in China, along with a variety 
of other fentanyl analogues.
In March 2017 furanylfentanyl was controlled in China. 
This control measure may deter at least the open 
manufacture and sale of this substance by such 
chemical companies and which are involved in the 
supply of the substance in that country.
Availability from Internet vendors
A structured search by the EMCDDA of online 
vendors (35) of furanylfentanyl on the surface web (36) 
was conducted in December 2016 (EMCDDA, 2017c). 
The search identified 46 vendors that appeared to be 
based in, and/or claim to have presence in China 
(n = 27 sites), the United States (n = 5 sites), Hong Kong 
(n = 3 sites), India (n = 1 site), South Korea (n = 1 site), 
Ukraine (n = 1 site) and the United Kingdom (n = 1 site). 
For the remaining 7 vendors, there was no apparent 
location mentioned. 
Twenty two of the sites provided quantities and prices 
for furanylfentanyl upon request. The remaining 24 sites 
listed quantities and prices. In brief:
 § Furanylfentanyl was usually offered in powder form. 
Typically it was listed as a ‘research chemical, not fit 
for human consumption’;
 § One site offered furanylfentanyl as a ready-to-use 
nasal spray and also ‘o-liquid’ intended for vaping in 
electronic cigarettes. This site also offered 
(35) This includes vendors that appear to be consumer-orientated as well as 
vendors which appear to be manufacturers and/or wholesalers (for 
example on B2B sites). It excludes those selling furanylfentanyl through 
online classified advertisements, social media, and user websites.
(36) The search of online vendors of furanylfentanyl was performed on 
19/12/2016 using the search strings: ‘buy furanylfentanyl’ (searches 
in English, Swedish and Danish, including variations in spelling). The 
first 100 results were recorded and the sites reviewed. Each identified 
vendor site was then scored for information on geographical location, 
quantities and prices, and substance marketing.
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furanylfentanyl in powder form mixed with either 
mannitol (ratio of 1:10) or caffeine (ratio of 1:25);
 § The minimum quantity offered was 1 g (n = 6 sites) 
with an mean price of EUR 54;
 § The mean price was (in EUR per gram): 19.3 for 10 g 
(n = 6 sites), 9.24 for 100 g (n =5 sites) and 5.299 for 
1 kg (n = 4 sites);
 § The maximum quantity offered was 5 kg with a price 
of EUR 29,467 (n = 1 site).
Prices were listed in United States Dollars on all 
24 sites (37).
In 4 collected samples reported by France, the 
furanylfentanyl was purchased from vendors on darknet 
marketplaces.
In a case reported by the United Kingdom, regarding a 
vendor on the darknet who was selling fentanils within 
the UK, the following prices were listed on the site (exact 
substances or mixtures are not reported, prices listed in 
Pounds Sterling (GBP)): ‘£6.66 for 250 mg; £11.20 
500 mg; £18.84 for 1 g; £34.15 for 2 g; £61.61 for 3.5 g; 
and £90.10 for 7 g’.
Prevalence of use 
No studies were identified that have investigated the 
prevalence of use of furanylfentanyl in the general 
population, but the available information does not 
suggest wide use of the substance. Given its 
pharmacology and that it is sold openly as a ‘legal’ 
replacement to illicit opioids, it would be expected that 
those looking for substitutes for opioids, which would 
include individuals who use illicit opioids, such as heroin 
and/or prescription opioids, may seek out 
furanylfentanyl and other fentanils. It also appears that 
there is interest in this substance by some psychonauts.
Furanylfentanyl has been detected with other opioids 
such as heroin, U-47,700, fentanyl, 2-fluorofentanyl, 
4F-isobutyrylfentanyl (4F-iBF) and carfentanil; as well as 
with cocaine, caffeine, paracetamol, and sugars/sugar 
alcohols (lactose, mannitol, inositol). The overall 
significance of these seizures is unclear; however, the 
identification of carfentanil is of serious concern given 
its potency. In addition, the identification of heroin and 
fentanyl in the seizures may suggest that furanylfentanyl 
is being supplied through the illicit heroin/opioid market.
(37) Prices listed in USD were converted to EUR according to the XE 
Currency Converter from the 11/01/2017 (USD 1 = EUR 0.95). The 
prices were then rounded up to the nearest EUR.
Section D. Health risks
D1. Acute health effects
D1.1. Animal data
Data on the acute toxicity, abuse liability or dependence 
producing potential of furanylfentanyl could not be 
identified.
D1.2. Human data
No clinical studies were identified that have examined 
the acute health effects of furanylfentanyl and/or its 
metabolites in humans. However, available non-clinical 
pharmacology data on furanylfentanyl (Tables 2 and 3) 
suggests functional similarity to fentanyl and morphine, 
which suggests that some toxicological similarity might 
exist (Moffat et al., 2016). 
Data from serious adverse events associated with 
furanylfentanyl are discussed in section D.1.2.2. Based 
on the data reported, the clinical features presented in 
cases of intoxication involving furanylfentanyl appear to 
be similar to those found with fentanyl and other opioid 
analgesics. These included unconsciousness or reduced 
level of consciousness, respiratory arrest or depression 
and miosis. 
Acute intoxications reported by the Member States
A total of 11 acute intoxications associated with 
furanylfentanyl were reported by three countries: 
Germany (4 cases), Sweden (5), and the United 
Kingdom (2). Of these, 1 was classed as a confirmed 
case (38), 1 as a probable case, and 9 as suspected 
(38) This case has been published in Helander et al. (2016) as case 14 in 
Table 1. In addition, case 13 in Helander et al. (2016), which relates 
to an intoxication involving furanylfentanyl and 
4-methoxybutryfentanyl, is the same individual as case 14. This case 
is not included in the main analysis below. Briefly, on arrival of the 
ambulance, the patient was unconscious with no response upon 
pain stimulation, apneic, and cyanotic. The patient had administered 
a liquid intranasally (by nasal spray) and, following ‘unsatisfactory 
nasal administration’ had also injected the liquid intramuscularly. 
4-Methoxybutyrfentanyl (11.0 ng/mL serum), furanylfentanyl 
(4.4 ng/mL serum), ethanol metabolites, MDPHP, and pregabalin 
were detected in biological samples taken from the patient. An 
unlabeled blue nasal spray brought in by the patient was analysed 
and found to contain mainly furanylfentanyl and <5% 
4-methoxybutyrfentanyl. Intravenous naloxone was administered 
(0.4 mg); the response to naloxone was not reported. The patient 
was treated in hospital for 2 days.
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cases (39). They occurred between November 2015 and 
September 2016 (40). Most of the cases were reported 
by poison centres.
Demographics
Of the 11 intoxications, 9 were male and 2 were female. 
The mean age of the male cases was 23 (median 22) 
and ranged from 15 to 32 years (data available for 
5 cases); the female cases were aged 20 and 32 years. 
Substances analytically identified 
Analytical confirmation was limited to the confirmed 
case and probable case.
In the confirmed case, furanylfentanyl, ethanol, 
5-EAPB (41), and MDPHP (42) were identified in the 
biological samples taken from the patient.
In the probable case, furanylfentanyl and mannitol were 
identified in a sample of the drug that was snorted by 
the patient.
Clinical features
Limited information was available on the clinical 
features of the intoxications. Overall, the features were 
generally consistent with µ-opioid agonist toxicity, but 
this information was only available from the probable 
case and some of the suspected cases (43). Clinical 
features included reduced level of consciousness or 
unconsciousness (5 cases) (44), respiratory arrest or 
depression (3) (45) and miosis (1). In one case 
(39) For the purposes of this report the following definitions are used. 
Confirmed case means that information on exposure to 
furanylfentanyl is available from analytical confirmation in one or 
more biological samples taken from a patient. Probable case means 
that information on exposure was only available from the analytical 
confirmation of furanylfentanyl in a drug sample and that there is a 
reasonable probability that the patient was exposed to that drug 
sample. Suspected case means that information on exposure is 
typically limited to the name of the substance that the patient 
believes that they have consumed and/or from packages containing 
the drugs that the patient is thought to have consumed. As a result, 
due to the lack analytical confirmation from biological samples, 
information on the features of the intoxication from probable and 
suspected cases should be interpreted with caution. Of note in this 
respect is that recently some products sold as ‘akrylfentanyl’ in 
Sweden actually contained fentanyl instead (Helander et al., 2017).
(40) In addition, Germany reported a non-fatal intoxication in which 
furanylfentanyl and lactose were identified in a sample of the drug 
that was apparently used by the patient (sample not quantified). 
However, insufficient information was available at the time of 
reporting to de-duplicate with other cases.
(41) Systematic name: 1-(1-benzofuran-5-yl)-N-ethylpropan-2-amine.
(42) Systematic name: 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-hexan-1-one.
(43) Information on the confirmed case was limited to him being alert 
(Reaction Level Scale (RLS) of 1), heart rate of 100/min, and blood 
pressure 140/80. 
(44) Including the confirmed case. 
(45) Including a suspected case which involved cardio-respiratory arrest 
10 minutes after inhalation of furanylfentanyl.
tachycardia and high body temperature were also 
reported. In the confirmed case, ethanol and stimulants 
were also identified in the biological sample from the 
patient. In addition, in 2 of the suspected cases the 
patients reported taking either other central nervous 
system depressants or stimulants. Information on 
exposure to other substances was either unknown or not 
reported in the remaining 8 cases.
Administration and response to naloxone
In 4 cases (the confirmed case and 3 suspected cases), 
naloxone was administered as an antidote. In the 
confirmed case 0.4mg s.c. and 0.4 mg i.v. were 
administered (no further details available); no 
information on the response is available. In the 
3 suspected cases, it was reported that the patients 
responded to treatment with naloxone (information on 
the dose and route are not available). 
The information was either unknown or not reported in 
the remaining 7 cases.
Seriousness and outcome
In 6 cases (the confirmed case, the probable case, and 
4 suspected cases) treatment in an emergency room/
hospital was required (46). The information was either 
unknown or not reported in the remaining 5 cases.
In 3 suspected cases the seriousness of the intoxication 
was classified as life-threatening (1 case) or severe (2). 
In 1 suspected case the seriousness was classed as not 
life-threatening. The information was either unknown or 
not reported in the remaining 7 cases.
In 2 cases it was reported that the patient recovered. 
The information was either unknown or not reported in 
the 9 remaining cases.
Route of administration
In the confirmed case, furanylfentanyl was administered 
nasally as a liquid (by nasal spray) and by intramuscular 
injection. In the probable case furanylfentanyl was 
snorted as a powder. In 5 of the suspected cases, 
furanylfentanyl was either ‘inhaled’ (1 case), administered 
nasally (2) or orally (2). The information was either 
unknown or not reported in the 4 remaining cases.
(46) Including the confirmed and probable case.
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Name of the substance/product used
In 9 cases, the patient was reported to have taken 
‘furanylfentanyl’. The information was either unknown or 
not reported in the 2 remaining cases.
Source of the substance
In 2 cases (the probable and a suspected case), 
furanylfentanyl was reported to have been sourced from 
the internet (47). The information was either unknown or 
not reported in the 9 remaining cases.
Physical form
In the confirmed case the physical form of 
furanylfentanyl used by the patient was a liquid in a 
nasal spray. In the probable case the physical form was 
a powder. In a suspected case the physical form was a 
liquid in a nasal spray. The information was either 
unknown or not reported in the remaining 8 cases.
Amount or dose administered
In 3 suspected cases the amount of furanylfentanyl 
used was reported: 5 mg nasally (1 case); 50 mg orally 
(1 case); 30 mg by inhalation. The information was either 
unknown or not reported in the remaining 8 cases.
Acute intoxications identified from other sources
In Surrey, British Columbia, Canada, a hospital 
emergency department identified a large increase in 
suspected opioid overdose events over a four-day period 
in July 2016. During this time they treated 43 patients 
with suspected opioid overdose. Just over 50 % of the 
patients (22 cases, 51 %) lost consciousness after 
smoking what they believed to have been crack cocaine. 
Samples of the drug used by the patients were analysed 
and found to contain a mixture of furanylfentanyl and 
cocaine. It was reported that most of the overdoses 
occurred within a small geographic area that has a high 
population of homeless persons and persons who use 
illicit drugs, including opioids and crack cocaine. Most of 
the overdoses occurred in males (36 cases, 84 %); the 
mean age of the patients was 42 years and ranged 
between 18 and 63 years. The majority of patients 
(40 cases, 93 %) arrived at the emergency department 
by ambulance. Most patients (37 cases, 86 %) received 
injectable naloxone before arriving at the emergency 
department. This included 12 patients who received it 
only from community members, 16 who received it only 
from paramedics, five who received it from both 
community members and paramedics, one who received 
(47) The probable case and a suspected case.
it from the fire department and paramedics, and one 
who received it from the fire department, community, 
and paramedics (for two patients, the source of 
naloxone was not known). Of particular note is that 
information from first responders, the community, and 
emergency department staff members highlighted that 
patients required high doses of naloxone, in some cases 
up to 3.0 mg (usual dose = 0.4 mg). Most of the patients 
(35 cases, 81 %) were treated and discharged within a 
few hours, two patients left without being seen by 
emergency department staff, and six patients were 
admitted to the hospital; among these, three were 
transferred to the intensive care unit, one of whom died 
(Klar et al., 2016a; Klar et al., 2016b).
Deaths reported by the Member States
A total of 23 analytically confirmed deaths associated 
with furanylfentanyl were reported by six countries: 
Estonia (4 deaths), Finland (1), Germany (4), 
Sweden (12)(48), United Kingdom (1), and Norway (1).
Demographics
Information on demographics was available for 19 
deaths. Of these, 17 were male and 2 were female. The 
mean age of the male decedents was 32.9 years 
(median 32) and ranged between 25 and 53 years; the 
age of the female decedents was 33 and 48 years.
Number of deaths by year
All 23 deaths occurred between November 2015 and 
February 2017; two deaths occurred in 2015, 19 in 2016 
and 2 in 2017.
Cause of death and toxicological significance
In 10 deaths, furanylfentanyl was reported to be the 
cause of death or to have contributed to death; in 2 of 
these deaths furanylfentanyl was the sole drug present. 
In 3 deaths furanylfentanyl was assumed to have 
contributed to death. In 3 cases the cause of death was 
reported as an “overdose with drugs or narcotics”, with 
no substances explicitly mentioned. In the remaining 
7 cases the cause of death had not yet been established, 
was not known, or was not reported.
A range of other substances were found in the deaths, 
including: benzodiazepines, gabapentinoids (pregabalin, 
gabapentin), ethanol, THC, amphetamine, MDMA, 
cocaine, antidepressants and antipsychotics. In 11 cases, 
furanylfentanyl was the sole opioid present. In the 
remaining 12 cases, other opioids detected were: 
(48) Seven of the deaths reported by Sweden are also reported in Guerrieri 
et al., (2017).
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fentanyl (6 deaths), acetylfentanyl (2), buprenorphine (2), 
tilidine (2), methadone (1), 4Cl-iBF (1), and tramadol (1).
No information was available regarding symptoms 
experienced by the decedents prior to death.
In an attempt to evaluate the toxicological significance of 
furanylfentanyl in the deaths reported, an assessment of 
the following evidence was considered in each case: 
presence and concentration (and pharmacological nature) 
of furanylfentanyl; presence and concentration (and 
pharmacological nature) of other drugs present (including 
alcohol); circumstances of death; pathological findings at 
post-mortem, and cited cause of death. This allowed 
categorisation of the significance of furanylfentanyl in the 
deaths as being of low significance (i.e. alternative cause 
of death), medium significance (i.e. furanylfentanyl may 
have contributed to toxicity/death but other drugs present 
may have been more toxicologically significant) or high 
significance (i.e. furanylfentanyl was cited as the cause of 
death or was assessed to have been likely to contribute to 
toxicity/death even in the presence of other drugs). In 
order to highlight potential interactions or contributing 
toxicology, the other substances found in the cases were 
characterised.
In 19 of the 23 deaths there was sufficient data to allow 
an assessment of the toxicological significance of 
furanylfentanyl. Of these, furanylfentanyl was either the 
cause of death or is likely to have contributed to death 
(even in presence of other substances) in 17 deaths. 
Whilst other drugs may have contributed some toxicity, a 
synergistic effect with furanylfentanyl would have been 
likely (e.g. other central nervous system depressants such 
as ethanol, benzodiazepines, other opioids, etc). 
Nevertheless, the pharmacological opioid nature of 
furanylfentanyl means the primary toxic contribution 
could be attributed to the drug and death may not have 
occurred if furanylfentanyl had not been used. In 2 cases, 
furanylfentanyl may have contributed to toxicity/death 
but other drugs were present that may be also 
toxicologically significant and contributed. In one case, an 
additional fentanyl derivative, 4-chloro-isobutyrfentanyl 
(4Cl-iBF) was detected (2.2 ng/g) along with a significant 
concentration of pregabalin (36 µg/g). In the other case, 
pregabalin and gabapentin were present at significant 
concentrations (27 µg /g and 90 µg/g, respectively) as 
well as fentanyl (0.38 ng/g), norbuprenorphine (1.3 µg/g), 
benzodiazepines (alprazolam and diazepam), 
alimemazine and methylphenidate. Overall, there is no 
defined “fatal” concentration that can be assigned to 
furanylfentanyl but in 17 cases where measured, post-
mortem blood concentrations between 0.2 to 1.54 µg/L 
and between 0.33 to 2.74 ng/g blood were recorded (the 
latter somewhat but not exactly equivalent to µg/L).
Circumstances of death
In 18 deaths, it was reported that the decedents were 
found dead. Of these, at least 12 were found in a home 
environment (their own or someone else’s) (49), 2 were 
found in a bathroom (no further information provided), 
and 1 was found outside. Consequently, it was not 
possible to identify or evaluate ante-mortem symptoms 
(especially in relation to acute intoxications). In 5 cases 
drug paraphernalia was found at the scene of death, 
including used injecting equipment. Information on the 
circumstances of death for the remaining 5 cases was 
not available.
In 4 deaths, the route of administration was reported: 
intravenous injection (2 cases), injected/oral (1), and 
snorted (1).
Circumstantial information, as well as analysis of hair 
samples, suggests that that some of decedents were 
high-risk drug users, including opioid users.
Deaths identified from other sources
At least 128 deaths associated with furanylfentanyl have 
been reported since 2015 in the United States (DEA, 
2016; Mohr et al., 2016).
D2. Chronic health effects
D2.1. Animal data
No studies were identified that have investigated the 
chronic health effects of furanylfentanyl in animals.
D2.2. Human data
No studies were identified that have investigated the 
chronic health effects of furanylfentanyl in humans.
D3. Factors affecting public health risks
D3.1. Availability and quality of the new psychoactive 
substance on the market
Furanylfentanyl is being sold by vendors on the Internet 
as a drug in its own right. It is sold in both retail and 
wholesale quantities. It has been sold as a ‘research 
(49) Including the bathroom (2 cases) and the couch (2 cases).
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chemical’ in several physical forms, including as 
powders and ready-to-use nasal sprays.
Limited information from seizures also suggests that 
furanylfentanyl is being sold on the illicit drug market, 
including the heroin/illicit opioid market.
D3.2. Availability of the information, degree of 
knowledge and perceptions amongst users 
concerning the psychoactive substance and its 
effects
Given the relatively recent availability of furanylfentanyl, 
the availability of information, degree of knowledge and 
perceptions amongst users concerning the substance 
and its effects are limited.
Information from user websites suggests that users are 
generally aware of the opioid-like (wanted and 
unwanted) effects of this substance. In addition, 
information from seizures suggests that some users, 
particularly those consuming furanylfentanyl in mixtures 
with other illicit opioids such as heroin, may not be 
aware that they are consuming the substance.
D3.3. Characteristics and behaviour of users
No studies were identified that have examined the 
characteristics and behaviours of users of 
furanylfentanyl. The available information, including 
deaths reported by the Member States and from user 
websites, suggests that furanylfentanyl is typically used 
in the home environment.
Some users may seek out furanylfentanyl because it was 
sold openly as a ‘legal replacement’ to illicit opioids; 
others may be experimenting with this opioid (so called 
psychonauts) to explore possible novel effects; whilst 
others still may seek to self-medicate pain or opioid-
withdrawal symptoms. It is likely that some users, 
particularly those consuming furanylfentanyl in mixtures 
with other illicit opioids such as heroin, may not be 
aware that they are consuming the substance.
Information from the deaths reported to the EMCDDA 
highlights that in 11 cases, furanylfentanyl was the sole 
opioid present. This suggests that approximately half of 
the decedents may have had no tolerance to opioids. In 
addition, the data also shows that polydrug use was 
common, including the use of other CNS depressants 
(Section D1.2).
D3.4. Nature and extent of health consequences
The limited information available on the pharmacology, 
dependence and abuse potential, and acute health 
effects of furanylfentanyl have been discussed above 
(Section A2, Section B, Section D1 and Section D2).
While the pharmacology and toxicology of 
furanylfentanyl largely remains unstudied, the available 
data, including its structural similarity to fentanyl, 
suggests that it is a potent opioid narcotic analgesic.
Among other adverse effects, opioid analgesics, such as 
fentanyl, produce dose-dependent respiratory 
depression. This risk is greater in opioid-naïve persons. 
Similar to other fentanils in overdose, the most serious 
acute risk arising from the use of furanylfentanyl 
appears to be from profound and rapid respiratory 
depression, which can lead to apnoea, respiratory arrest, 
and death. This risk may be exacerbated given:
 § the difficulty of diluting fentanils (50);
 § the lack of experience of users with this new 
substance (in terms of a lack of familiarity with the 
effects and dose of the substance);
 § the concomitant use of other CNS depressants (such 
as other opioids, benzodiazepines, gabapentanoids, 
and ethanol (alcohol));
 § in some cases no apparent tolerance to opioids; and,
 § the environment in which the substance is used — 
typically in the home environment.
In almost 80 % of the deaths reported to the EMCDDA 
the individuals were found dead, often in a home 
environment (their own or someone else’s). It is 
reasonable to assume that in at least some of these 
cases the poisoning with furanylfentanyl was so severe 
that they were unable to call for help.
Importantly, given what is known about the 
pharmacology of furanylfentanyl it is reasonable to 
assume that the antidote naloxone will reverse poisoning 
(overdose) caused by exposure to the substance. Recent 
clinical and community experience in treating probable 
and suspected furanylfentanyl poisoning cases supports 
this assertion (Klar et al., 2016a; Klar et al., 2016b). 
However, due to the potency of the fentanils, their 
half-lives, and the dose used, larger than normal doses 
as well as repeated doses of naloxone may be required 
to fully reverse poisoning (CDC, 2013; FDA, 2016). Again, 
clinical (51)and community experience in treating 
poisonings by fentanils, including furanylfentanyl, 
(50) This is also reflected in data from seizures of tablets containing 
fentanils which have shown large variability in the amount of the 
substance present (de Boer et al., 2003).
(51) Including paramedics and hospital emergency room staff. 
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supports this assertion (Klar et al., 2016a; Klar et al., 
2016b; Sutter et al., 2017). Stocks and availability of the 
antidote naloxone, as well as adequacy of training in how 
to resuscitate poisoned patients may need to be 
assessed.
In a recent outbreak of poisonings in California, United 
States, which was caused by counterfeit analgesic 
medicines containing large doses of fentanyl (Sutter et 
al., 2017), it was highlighted that:
 § Sufficient antidote stocking was an important factor 
as the supplies of naloxone at the hospital were 
quickly depleted because of the large number of 
patients that presented over a short period of time, as 
well as the need of some patients for several 
milligrams of naloxone as bolus dosing and prolonged 
infusion times.
 § The hospital required emergency deliveries of 
naloxone to keep supplies sufficient for patient care.
 § A notable clinical difference observed was not only 
that some patients required prolonged naloxone 
infusions but also the recurrence of respiratory 
depression in the hospital after 8 hours of 
observation without naloxone.
In addition to users, accidental exposure of 
furanylfentanyl and other fentanils — such as skin 
contact, inhalation, or ingestion — pose a serious risk of 
poisoning to the public, law enforcement, emergency 
personnel, as well as medical and forensic laboratory 
personnel (Section A).
Adding to the challenges posed by the fentanils is 
evidence from Europe, the United States, and Canada 
that they are being sold to unsuspecting users in/as 
heroin or other illicit opioids, counterfeit medicines 
(including commonly used opioid analgesics and 
benzodiazepines), cocaine, and other illicit drugs. As 
users will be unaware of this, it increases the risk of 
severe and fatal poisoning in both opioid users and 
especially other groups who may have no existing 
tolerance to opioids (Klar et al., 2016a; Klar et al., 2016b; 
HCCCSF, 2016a; HCCCSF, 2016b; SFDPH, 2015; 
Tomassoni et al., 2017). Non-opioid users are unlikely 
neither to be aware of these risks nor to have access to 
community-based naloxone programmes, including 
take-home naloxone (EMCDDA, 2015; EMCDDA, 2016b).
D3.5. Long-term consequences of use
There is no data regarding the long-term consequences 
of using furanylfentanyl.
D3.6. Conditions under which the new psychoactive 
substance is obtained and used, including context-
related effects and risks
There is limited data on the conditions which 
furanylfentanyl is obtained and used. It appears 
furanylfentanyl has been sold on the surface web and 
darknet marketplaces, typically as powders. It has also 
been sold as ready-to-use nasal sprays. A small number 
of e-liquids for use in electronic cigarettes have also 
been reported.
Limited information suggests that it may also have been 
sold on the illicit drug market, including the illicit opioid/
heroin market in some countries.
In almost 80 % of the deaths reported to the EMCDDA 
the individuals were found dead, often in a home 
environment (their own or someone else’s).
Data reported to the EMCDDA suggests that ready-to-
use nasal sprays and e-liquids containing fentanils are 
increasing in availability. It will be important to study 
what effect, if any, these products have had on 
increasing physical availability, attractiveness, and 
social acceptance to existing and new groups of users.
Section E. Social risks
While there have been no studies on the social risks of 
furanylfentanyl, it is likely that some of the risks are 
similar to those associated with opioids such as fentanyl 
and heroin.
E1. Individual social risks
There is no information on whether the use of 
furanylfentanyl causes individual social risks; however, 
they may have some similarities with those associated 
with illicit opioids, including fentanyl and heroin. These 
may impact on education or career, family or other 
personal and social relationships and may result in 
marginalisation.
E2. Possible effects on direct social environment
There is no information on the possible effects of 
furanylfentanyl on the direct social environment; 
however, they may have some similarities with those 
associated with the use of illicit opioids.
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E3. Possible effects on society as a whole
There is no specific information on the possible effects 
of furanylfentanyl on society as a whole.
As discussed above, accidental exposure of 
furanylfentanyl and other fentanils — such as skin 
contact, inhalation, or ingestion — also poses a serious 
risk of poisoning to those who may come into contact 
with the substances. This includes the family and 
friends of users, law enforcement, emergency personnel, 
medical and forensic laboratory personnel as well as 
custodial settings and postal services. Where required, 
these risks should be assessed and appropriate 
procedures, training, and protective measures should be 
implemented. This may include training in resuscitation 
and adequate provision of naloxone to reverse poisoning.
E4. Economic costs
There are no data on the effects of furanylfentanyl in 
respect to its health and social costs. However, it is likely 
that even at low prevalence this drug has the potential to 
generate relatively high costs to health services.
E5. Possible effects related to the cultural 
context, for example marginalisation
There is no specific data on the possible effects of 
furanylfentanyl related to the cultural context.
E6. Possible appeal of the new psychoactive 
substance to specific population groups within 
the general population
Whilst no specific examples are available on the 
possible appeal of furanylfentanyl to specific user 
groups, it is reasonable to assume furanylfentanyl may 
be sought by those looking for substitutes for illicit 
opioids, such as heroin and/or prescription opioids.
In addition, concerns exist over novel dosage forms 
— such as ready-to-use nasal sprays and e-liquids for 
vaping — which have the potential to make the use of 
fentanils easier (with similar effects to injecting) and 
more socially acceptable. Further research is required 
on this topic to better understand the risks.
Section F. Involvement of organised 
crime
F1. Evidence that criminal groups are 
systematically involved in production, trafficking 
and distribution for financial gain
There is no specific information to suggest the 
involvement of organised crime or established criminal 
groups in the manufacture, distribution and supply of 
furanylfentanyl.
In the cases where the origin of the seizures/collected 
samples reported to the EMCDDA was known, the 
country of origin indicated was: Poland (20 seizures); the 
United Kingdom (1) and China (1).
Information from seizures in four Member States that 
were reported to Europol shows that some 
furanylfentanyl on the market in Europe has been 
produced by chemical companies based in China.
In addition to importation, the seizure of an illicit 
laboratory in Europe in 2013 that was producing 
fentanils, that may have included furanylfentanyl, 
suggests that the production in Europe cannot be 
excluded. This case demonstrates the capability to 
manufacture fentanils exists within the European Union.
In 7 seizures made by Belgian customs the country of 
destination of the seizure was: Spain (1), Germany (3), 
France (1), the Netherlands (1) and Slovenia (1).
F2. Impact on the production, trafficking and 
distribution of other substances, including 
existing psychoactive substances as well as new 
psychoactive substances
There is no information on the impact of furanylfentanyl 
on the production, trafficking and distribution of other 
substances, including existing psychoactive substances 
as well as new psychoactive substances.
F3. Evidence of the same groups of people being 
involved in different types of crime
No information has been received by Europol of 
evidence of the same groups of people being involved in 
different types of crime in connection with 
furanylfentanyl.
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F4. Impact of violence from criminal groups on 
society as a whole or on social groups or local 
communities (public order and safety)
No specific information has been received by Europol on 
incidents of violence in connection with furanylfentanyl.
F5. Evidence of money laundering practices, 
or impact of organised crime on other 
socioeconomic factors in society
No specific information has been received by Europol on 
incidents of money laundering or impact of organised 
crime on other socioeconomic factors in society in 
connection with furanylfentanyl.
F6. Economic costs and consequences (evasion 
of taxes or duties, costs to the judicial system)
There are no published data to be able to determine the 
impact of furanylfentanyl in this area.
F7. Use of violence between or within criminal 
groups
There are no published data to be able to determine the 
impact of furanylfentanyl in this area.
F8. Evidence of strategies to prevent 
prosecution, for example through corruption or 
intimidation
There are no published data to be able to determine the 
impact of furanylfentanyl in this area.
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Council Decision
published in Official Journal of the European Union, L 306/19, 
on 22.11.2017 
COUNCIL IMPLEMENTING DECISION (EU) 2017/2170 of 15 November 2017 on 
subjecting N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide 
(furanylfentanyl) to control measures
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk-assessment and control of new psychoactive substances (1), and in 
particular Article 8(3) thereof,
Having regard to the proposal from the European Commission, 
Having regard to the opinion of the European Parliament (2), 
Whereas:
(1) A risk-assessment report on the new psychoactive substance N-phenyl-N-[1-(2-
phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) was drawn up in accordance 
with Decision 2005/387/JHA by a special session of the extended Scientific Committee of the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and was subsequently 
submitted to the Commission and to the Council on 24 May 2017.
(2) Furanylfentanyl is a synthetic opioid and is structurally similar to fentanyl, a controlled 
substance widely used in medicine for general anaesthesia during surgery and for pain 
management. Furanylfentanyl is also structurally related to acetylfentanyl and acryloylfentanyl, 
which were both the subject of an EMCDDA–Europol Joint Report in December 2015 and 
November 2016.
(3) Furanylfentanyl has been available in the Union since at least June 2015 and has been 
detected in 16 Member States. In most cases, it was seized in powder form, but also in liquid 
form and as tablets. The detected quantities are relatively small. However, such quantities 
should be seen in the context of the potency of the substance.
(4) Twenty-two deaths associated with furanylfentanyl have been reported by five Member 
States. As regards at least ten of those deaths, furanylfentanyl was the cause of death or is 
likely to have contributed to the death. In addition, 11 acute non-fatal intoxications associated 
with furanylfentanyl were reported by three Member States.
(5) There is no information suggesting the involvement of organised crime in the manufacture, 
distribution (trafficking) and supply of furanylfentanyl within the Union. The available data 
suggest that furanylfentanyl is produced by chemical companies based in China.
(6) Furanylfentanyl is sold online in small and wholesale amounts as a ‘research chemical’, 
typically as a powder and as ready-to-use nasal sprays. Information from seizures suggests 
that furanylfentanyl may have also been sold on the illicit opioid market.
(7) Furanylfentanyl has no recognised human or veterinary medical use in the Union. There 
are no indications that furanylfentanyl may be used for any other purpose apart from as an 
analytical reference standard and in scientific research.
(1) OJ L 127, 20.5.2005, p. 32.
(2) Opinion of 24 October 2017 (not yet published in the Official Journal)
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(8) The risk-assessment report reveals that many of the questions related to furanylfentanyl are 
due to the lack of data on the risks to individual health, risks to public health, and social risks, 
and could be answered through further research. However, the available evidence and 
information on the health and social risks that the substance poses, given also its similarities 
with fentanyl, provide sufficient grounds for subjecting furanylfentanyl to control measures 
across the Union.
(9) Furanylfentanyl is not listed for control under the 1961 United Nations Single Convention 
on Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic 
Substances. The substance is not currently under assessment by the United Nations system.
(10) Given that ten Member States control furanylfentanyl under national drug control 
legislation and three Member States control furanylfentanyl under other legislation, 
subjecting this substance to control measures across the Union would help avoid the 
emergence of obstacles in cross-border law enforcement and judicial cooperation, and 
would help protect the Union from the risks that its availability and use can pose.
(11) Decision 2005/387/JHA confers upon the Council implementing powers with a view to 
giving a quick and expertise-based response at Union level to the emergence of new 
psychoactive substances detected and reported by the Member States, by subjecting those 
substances to control measures across the Union. As the conditions and procedure for triggering 
the exercise of such implementing powers have been met, an implementing decision should be 
adopted in order to subject furanylfentanyl to control measures across the Union.
(12) Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision, which implements Decision 2005/387/JHA.
(13) Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption 
and application of this Decision, which implements Decision 2005/387/JHA.
(14) The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking 
part in the adoption of this Decision, which implements Decision 2005/387/JHA, and is not 
bound by it or subject to its application,
HAS ADOPTED THIS DECISION:
Article 1
The new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-
carboxamide (furanylfentanyl) shall be subject to control measures across the Union.
Article 2
By 19 November 2018 Member States shall take the necessary measures, in accordance 
with their national law, to subject the new psychoactive substance referred to in Article 1 to 
control measures and criminal penalties, as provided for under their legislation, in 
compliance with their obligations under the 1971 United Nations Convention on 
Psychotropic Substances.
Article 3
This Decision shall enter into force on the day following that of its publication in the Official 
Journal of the European Union.
This Decision shall apply in accordance with the Treaties.
Done at Brussels, 15 November 2017.
For the Council 
The President 
J. AAB
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